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Abstract
Novel serum biomarkers for lung cancer early diagnosis and clinical outcome
Fanmao Zhang, B.S.
Advisory Professor: Xifeng Wu, M.D., Ph.D.
The five-year survival rate for all stages of lung cancer combined is only
17%, which has changed little over the past 40 years. Despite the tremendous
efforts made, serum biomarkers with clinical utility for lung cancer early detection
and clinical outcome prediction are still lacking. Metabolic alterations have been
recognized as an emerging hallmark of cancer. We aimed to investigate the
metabolic changes associated with lung cancer and to identify novel clinically
applicable serum biomarkers for lung cancer early diagnosis and clinical outcome.
Serum metabolites are potential biomarkers for lung cancer early detection.
We first performed global metabolomic profiling followed by targeted validation of
individual metabolites in a case-control design of 386 lung cancer cases and 193
matched controls. We then validated the most significant metabolite bilirubin as a
risk marker for lung cancer incidence and mortality in a large prospective cohort
comprised of 425,660 participants. In this cohort, the inverse association was only
seen in male smokers. For every 0.1 mg/dL decrease of bilirubin, the risks for lung
cancer incidence and mortality increased by 5% and 6%, respectively (both P <
0.001).
We next investigated pre-treatment laboratory tests indicative of a patient’s
overall metabolic status, as biomarkers for non-small cell lung cancer (NSCLC)
clinical outcome. We assessed seven pre-treatment serum laboratory test levels
vi

in 2,675 NSCLC patients, including 623 early stage and 2,052 advanced stage
patients. Among 978 advanced stage NSCLC patients we studied who were
treated with platinum-based chemotherapy, lower than normal levels of albumin,
higher than normal levels of alkaline phosphatase and lactate dehydrogenase
were all associated with worse 2-year overall survival, after adjusting for other
variables. In addition, there was a cumulative effect among these three adverse
laboratory test levels.
In conclusion, low serum bilirubin levels are associated with higher risks of
lung cancer incidence and mortality in male smokers and may be used to identify
higher risk smokers for lung cancer. In addition, pre-treatment laboratory test
levels indicative of metabolic status could be utilized to enhance predictions of
survival among advanced stage NSCLC patients treated with platinum-based
chemotherapy. Taken together, our results suggested that metabolic alterations
associated with lung cancer could serve as novel serum biomarkers with clinical
significance for lung cancer early detection and clinical outcome.
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Chapter 1. Introduction
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1.1. Lung Cancer Epidemiology

1.1.1. Incidence and mortality
Approximately 1.6 million lung cancer cases are newly diagnosed each
year worldwide, accounting for about 13% of all cancer cases (1). Lung cancer is
the most common cancer in males and the fourth most commonly diagnosed
cancer in females worldwide (1). In the United States, approximately 224,210
cases of lung cancer are expected to be newly diagnosed in 2014 (2). It’s the
second most common cancer in both males and females, accounting for about 13%
of all cancer cases diagnosed. In the US, the incident rates of lung cancer have
been declining since the mid-1980s in males, and have just started declining in
females since the mid-2000s. From 2006 to 2010, incidence rates decreased by
1.9% per year in males and by 1.2% per year in females (2). The median age at
diagnosis is approximately 70 years (3). Lung cancer incidence rates are different
among ethnic groups. In the US, incidence rates are highest among black males,
which is 40% higher than in white males.
Worldwide, lung cancer accounts for nearly 1.4 million deaths each year –
18% of overall cancer-related mortality (3). It is the leading cause of
cancer-related mortality in males, and the second leading cause of cancer-related
mortality in females worldwide (1). In the US, approximately 159,260 patients are
expected to die from lung cancer in 2014. It’s the leading cause of cancer-related
mortality in both males and females, accounting for about 27% of all
2

cancer-related mortality in the US, more than the mortality attributed to the next
four most deadly cancers combined (breast, prostate, colon and pancreatic
cancers) (2). Mortality rates started declining in the early 1990s in males, and
mid-2000s in females. From 2006 to 2010, mortality rates decreased by 2.9% per
year in males and by 1.4% per year in females. On the other hand, lung cancer
incidence and mortality rates are still on the rise in many other countries (3).
Worldwide, the highest lung cancer incidence rates in males are observed
in Central and Eastern Europe, Northern America, while the lowest rates are
observed in sub-Saharan Africa. In females, the highest lung cancer incidence
rates are observed in Northern America and Northern Europe, and the lowest
rates are observed in Africa as well (1).

1.1.2. Risk factors
Tobacco smoking has been recognized as the most predominant risk factor
for lung cancer since the 1950s. Tobacco smoking is estimated to account for 80%
of the worldwide lung cancer burden among males and over 50% of the burden in
females (1). However, less than 10% of ever-smokers develop lung cancer. Both
smoking intensity (i.e. number of cigarettes smoked per day) and duration of
smoking increase lung cancer risks. Other factors of smoking influencing lung
cancer risk include age starting to smoke, time since quitting and types of tobacco
products smoked. Lung cancer risks are at least ten-times higher among smokers
compared to those who never smoked, in both males and females (4). Former
smokers have a lower risk of lung cancer, although risk is still higher among
3

former smokers compared to never-smokers. The observed differences in lung
cancer incidence rates across countries and between genders are primarily due to
differences in the smoking epidemic (1). Besides cigarettes, cigar or pipe smoking
also increases lung cancer risk.
Exposure to second-hand smoking is a major risk factor for those who do
not smoke. It is estimated that 40% of non-smokers in the US are exposed to
second-hand smoking, which increases lung cancer risk by up to 30% and
contributes to around 3,000 lung cancer deaths each year.
Exposure to radon gas, which is commonly released from construction
materials, is responsible for over 20,000 lung cancer cases each year in the
United States, making it the second leading risk factor for lung cancer in North
America and Europe (2). Other known risk factors include environmental or
occupational exposure asbestos, air pollution, diesel exhaust, radiation, polycyclic
aromatic hydrocarbons (PAHs) as well as certain metals (arsenic, chromium and
cadmium). There is also interaction among these risk factors, e.g. asbestos
exposure and cigarette smoking have been shown to jointly increase lung cancer
risk (5).
Of note, although smoking is less prevalent in Chinese females (less than
4% adults) compared to those in certain European countries such as Germany
and Italy (about 20% adults), lung cancer incidence rates are higher among
Chinese females, presumably reflecting indoor air pollution from stoves fueled by
coal and without ventilation and from cooking fumes in China (1). Other risk
factors include a family or personal history of cancer as well as a medical history
4

of tuberculosis. Genetics also plays a contributing role in lung cancer
carcinogenesis, particularly among patients with early age-onset (3).

1.2. Lung Cancer Treatment and Survival
Lung cancer can be broadly categorized into two major histopathologic
groups: small-cell lung cancer (SCLC, 14% of cases) and non-small cell lung
cancer (NSCLC, 84% of cases) for the purposes of treatment (6). NSCLCs are of
epithelial cells origin, while SCLCs are of endocrine cells origin. NSCLC can be
further classified into several subtypes based on different characteristics of tumor
cells, which includes adenocarcinoma (~40%), squamous cell carcinoma (25% 30%), large cell carcinoma (10% - 15%) as well as bronchioloalveolar carcinoma
(3).
Treatment regimens include surgery, radiation therapy, chemotherapy and
targeted therapy, depending on type and stage of disease, as well as molecular
characteristics of the tumors (6). For SCLC, radiation therapy alone is the
standard treatment for limited disease (LD), while radiation therapy in combination
with chemotherapy is the standard treatment for extensive disease (ED) (6). A
majority of patients experience at least temporary remission under this regimen,
although they often experience recurrence later.
For NSCLC patients with localized diseases, surgery is usually the
treatment of choice. Survival is improved when chemotherapy is administered
after surgery for most of these patients. About 30% of early stage patients will
develop recurrence or progress to metastatic disease. Therefore, besides overall
5

survival, prevention of recurrence and progression is another major concern for
early stage NSCLC patients. For advanced stage NSCLC patients, chemotherapy,
radiation therapy or a combination of both are used for treatment (6) (Figure 1).
Currently, the standard treatment for advanced stage NSCLC patients is
platinum-based chemotherapy, with an overall response rate of 17% to 32% and a
moderately improved survival among patients. Radiation therapy is usually
administered either concurrently or sequentially in combination with
chemotherapy. However, many patients develop severe toxic effects from the
treatment. Therefore, patients with advanced stage NSCLC are often treated with
palliative purposes to reduce symptoms and to improve quality of life. Targeted
therapies are used to treat advanced stage NSCLC as well (3).

6

Figure 1. Non-Small Cell Lung Cancer Treatment Patterns by Stage, 2008.

Chemo indicates chemotherapy (may include common targeted therapies); RT,
radiation therapy. Percentages do not sum to 100% due to rounding. Data source:
NCDB (6). Reprinted by permission from CA CANCER J CLIN, copyright (2012).
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Overall outcomes for all stages of lung cancer have improved in recent
years. The 1-year survival rate has increased during the past several decades
primarily due to improvements in surgical techniques and chemotherapy for lung
cancer. However, the overall 5-year survival rate for lung cancer has remained
relatively unchanged at approximately 15% for the past two decades (2). The
5-year survival rates for local, regional and distant diseases are 54%, 26% and 4%
(Figure 2), respectively. Therefore, early detection is the best way to reduce lung
cancer mortality. However, only 15% of lung cancer cases are diagnosed at the
local stage. Most lung cancer patients are diagnosed at inoperable advanced
stages when the prognosis is particularly dismal, as the early stage disease is
typically asymptomatic (3). The overall 5-year survival rate is 6% for SCLC and 18%
for NSCLC (6). Among NSCLCs, patients with adenocarcinoma usually have
better prognosis compared to those with other subtypes, while patients with large
cell carcinoma usually have worse prognosis since tumors are often poorly
differentiated and metastasize early.

8

Figure 2. Five-Year Relative Survival Rates (A) and Stage Distribution (B) of
Lung Cancer by Race and Stage at Diagnosis.
United States, 2003 to 2009 (2). Reprinted by permission from CA CANCER J
CLIN copyright (2014).
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1.3. Lung Cancer Prognostic and Predictive Factors
Survival time varies significantly among lung cancer patients, with some
patients surviving years, and others less than a few months. Besides the
well-known TNM stage, several other factors have been shown to affect clinical
outcomes among NSCLC patients. These factors can be classified as prognostic
or predictive markers. A prognostic factor is a characteristic that indicates the
course of disease and clinical outcomes irrespective of treatments – it indicates
the effect of the tumor on the patient. A predictive marker is a characteristic that
indicates better clinical outcomes from a specific treatment, which determines the
effect of treatment on the tumor (7, 8). Prognostic factors may help identify
patients who are more likely to experience recurrence or progression to advanced
disease and facilitate physicians making treatment plans accordingly, while
predictive factors could be used to predict treatment responses, thus maximizing
responses from effective treatments, minimizing toxicity associated with
ineffective cytotoxic treatments and therefore improve overall survival and quality
of life with personalized treatments. Several variables have been identified as
prognostic/predictive markers for NSCLC clinical outcomes as our understanding
in the molecular mechanisms underlying NSCLC tumorigenesis evolves (8).
Prognostic factors for NSCLC can generally be grouped into three
categories: patient-related factors (e.g. age, gender, performance status and
comorbidity, etc.), tumor-related factors (e.g. TNM stage, tumor histology and
grade, etc.) and environmental factors (e.g. nutritional status, etc.). Several
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molecular markers have been well studied as prognostic factors for NSCLC, e.g.,
excision repair cross-complementation group 1 protein (ERCC1), P53, KRAS and
EGFR (7). Several studies have also investigated clinical and laboratory variables
as prognostic factors for lung cancer clinical outcomes, and to guide selection of
treatment plan. Among those, only a few are validated and used clinically as
prognostic factors, e.g. TNM stage and performance status of patients. The
clinical utility of other factors, e.g. clinical laboratory tests, although suggested by
some studies, are still controversial and requires further large studies, preferably
in large randomized clinical trials (RCTs) (9).

1.4. Lung Cancer Screening
In 2011, the National Lung Screening Trial (NLST) concluded that low-dose
helical computed tomography (LDCT) screening of high-risk individuals could
reduce lung cancer mortality by 20% among current and former heavy smokers
compared with standard chest x-ray based on findings from 53,454 participants
enrolled (10). Based on these findings, LDCT screening according to NLST
selection criteria, i.e., current or former smokers aged 55-74 years with at least 30
pack-years of smoking history and no more than 15 years since quitting, has been
recommended by the majority of professional organizations in the US (11-14).
Moreover, it has recently been reported that participants with the highest risk for
lung cancer deaths accounted for the most screening-prevented lung-cancer
deaths and benefitted most from LDCT, while very few deaths were prevented
among those at lowest risk (15). However, the feasibility of large-scale screening
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is limited by a false positive rate of greater than 95% (10, 11). Biomarkers are
urgently needed for improving risk prediction for lung cancer beyond smoking
variables alone to reduce false positives and shift the balance towards higher
cost-effectiveness for screening and early detection of lung cancer.

1.5. Cancer Biomarkers
According to the definition of National Cancer Institute, a biomarker is “a
biological molecule found in blood, other body fluids or in tissues that is a sign of a
normal or abnormal process, or of a condition or disease” (16). Accordingly,
sources of biomarkers include whole blood/plasma/serum, urine, sputum, tissue
or peripheral blood lymphocyte, etc. Cancer biomarkers can be used to assess
exposure or disease risk, screen the general population, aid in the diagnosis and
clinical staging of cancer, predict response or resistance to a specific treatment,
monitor disease course to assess recurrence or progression, or serve as
prognostic factors for disease, etc. (16). Cancer biomarkers can be applied across
the cancer continuum, offering one of the best ways for risk prediction, early
diagnosis, therapeutic response prediction and prognosis.

1.5.1. Classification of biomarkers
Generally, cancer biomarkers can be produced from either the tumor itself
or other tissues in response to the presence of tumor or other conditions
associated with the tumor. There are four categories of cancer molecular
biomarkers: (i) risk biomarkers, which are factors associated with or contributing
12

to the carcinogenesis process, examples of which include genetic risk factors,
high estradiol levels for breast cancer patients as well as HPV infection for
cervical cancer patients; (ii) released biomarkers, which are factors released in
abnormal levels in cancer patients due to anatomical or metabolic abnormality
associated with tumor, examples of which include high PSA levels in prostate
cancer patients or blood in stools in colorectal cancer patients; (iii) response
biomarkers, e.g. antibodies and acute-phase reactants (17), which are factors
generated by the body in response to the tumor; (iv) carcinogenesis biomarkers,
such as DNA mutation or hyper-methylation, which are shed by the tumor and
products of the carcinogenic process (18).
There are potential limitations associated with each class of biomarkers.
Risk biomarkers could be used to predict individual’s cancer risk. However, for a
given risk biomarker, only a small percentage of individuals with the risk factor
would develop cancer. Therefore, the integration of several risk biomarkers into a
risk prediction model is necessary to improve the prediction. Release biomarkers
are present in abnormal levels in cancer patients due to the presence of the tumor.
However, other conditions could also lead to abnormal levels of these factors
since they are often non-specific molecular biomarkers for cancer. Similarly, many
other pathological conditions could lead to generation of response biomarkers by
the body. Conversely, carcinogenesis biomarkers are a group of markers that are
specific for patients with different types of cancer. Depending on the purpose and
design of the study, carcinogenesis biomarkers may be identified for early
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diagnosis of cancer, although they are more likely to be present in metastatic or
invasive tumors.

1.5.2. Blood-based biomarkers
Blood/serum/plasma is the most common source for biomarker studies and
the most used biological material in the clinic. It offers several advantages over
other biological samples: (i) it is minimally invasive to obtain blood samples; (ii) it’s
abundant and could be obtained serially to allow for disease follow-up; (iii) blood
serves as a metabolic source/sink and reflects the cumulative impact of all organ
systems including perturbations relating to disease. However, one of the major
disadvantages with blood for biomarker studies is that analytes in blood, including
RNAs, proteins and metabolites, usually present at levels spanning a large range,
making it difficult to measure all analytes accurately (19). Nevertheless,
blood/serum/plasma is still the most cost-effective and widely used source for
biomarker studies. Unfortunately, there are not many validated serum biomarkers
of sufficient sensitivity and specificity that can be applied clinically.

1.5.3. Tumor-derived biomarkers
Tissue is another important source for cancer biomarker studies.
Tissue-based biomarkers from the tumor are more specific to the underlying
cancer and reflect more directly the pathogenic process compared to biomarkers
from other sources. However, the sampling procedure is usually invasive, and
therefore more difficult and costly to obtain. Moreover, tumor samples are usually
14

obtained at a single time point (at the time of surgery) and are less amenable for
tracking disease status or progression.
Biomarkers with clinical significance can be applied along the cancer
continuum to substantially reduce cancer burden through risk prediction,
prevention, early detection, personalized treatment and disease monitoring after
treatment. During the past decade, there have been substantial new discoveries
on cancer biomarkers with the application of large-scale high-throughput
technologies. However, thus far, very few biomarkers have been validated and
applied in the clinic. One major problem is the lack of validation for the identified
biomarkers. Many studies lacked a replication phase, and few biomarkers have
been prospectively validated, which minimizes biases and reverse causality.
Another major concern is the relatively low sensitivity or specificity of the
candidate biomarkers. Many potential biomarkers don’t have sufficient sensitivity
and specificity to be useful in the clinic for decision-making purposes.
Nevertheless, those markers that are not specific to cancer could serve as
markers of other diseases and pathologies that are associated with cancer,
including inflammation, anemia, malnutritrion, cachexia, etc.

1.6. Cancer Metabolism
It is well established that cancer cells undergo profound changes in cellular
metabolism to sustain the additional demands for energy and synthesis of
essential biochemical precursors required for uncontrolled proliferation (20).
Metabolic reprogramming has been increasingly recognized as an emerging
15

hallmark of cancer, providing cancer cells with energy and biosynthetic materials
to support continuous cell growth and proliferation in cancer (21). Alterations in
several pathways, including glycolysis, glutaminolyis and mitochondrial
biogenesis are among the most significant alterations of cancer cell metabolism,
supporting both cancer initiation and progression. They provide cancer cells both
the energy required as well as metabolites for synthesizing macromolecules and
organelles for cell proliferation. For example, increased glycolysis in cancer cells
diverts glycolytic intermediates to molecules used for generating nucleosides and
amino acids, which facilitates macromolecules biosynthesis (22). Therefore, a
deep understanding of the fundamental metabolic changes that occur during lung
cancer development could lead to the identification of novel biomarkers for lung
cancer early diagnosis.

1.7. Metabolomics
Metabolomics is the systematic, unbiased study of the unique chemical
fingerprints generated by metabolic processes that can inform the cellular
processes of an organism (23). In the first issue of the new decade, Nature asked
a selection of leading researchers and policy-makers in five areas where their
fields would be ten years from then, and one of the fields chosen was
metabolomics (23). In contrast to the widely studied genomics and
transcriptomics, metabolomics is an emerging science. Metabolites include the
end products of the cellular processes, which represent the distal read-out of the
cellular state. It is therefore thought that metabolomic profiling reflects
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physiological functions and pathological characteristics in greatest detail. As part
of a system biology perspective, metabolomic profiling has become an important
complement to the other “omic” approaches including genomics, epigenomics,
transcriptomics, and proteomics and is emerging as an important tool to identify
biomarkers for the early detection, diagnosis, and prognosis of cancers (24).
Multiple technologies have been applied for metabolomic profiling,
including nuclear magnetic resonance (NMR), high pressure liquid
chromatography (HPLC), gas chromatography/mass spectrometry and liquid
chromatography/mass spectrometry (GC/MS and LC/MS). Among these, NMR
has the limitation of defining only named compounds, although it is sensitive and
high-throughput. HPLC requires an external standard and identifies compounds
based solely on their chromatographic retention time. On the other hand, GC/MS
and LC/MS are sensitive and allow for both identification of known metabolites
and characterization of unknown compounds (24).
Several studies have utilized metabolomic profiling to reveal metabolic
alterations associated with various malignancies, including breast (25), colorectal
(26), esophageal (27), gastric (28), liver (29), kidney (30), oral (31), pancreatic (32)
and prostate (24) cancers. Recently, a few studies have investigated metabolic
profiles of lung cancer patients (33-35). However, they only targeted and
measured a small, selected number of metabolites.

1.8. Hypothesis and Rationale

1.8.1. Hypothesis I: Global metabolomic profiling could identify serum metabolites
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that are differentially expressed during lung cancer development, which
could consequently be used as novel biomarkers for the early detection of
lung cancer.
Cancer cells have been known to acquire altered cellular metabolism to
sustain the additional demands for energy and other biochemical precursors for
uncontrolled proliferation. Metabolomic profiling offers a functional readout of the
physiological state and a comprehensive picture of the metabolic changes
associated with cancer development. We therefore hypothesized that global
metabolomics profiling followed by target validation of individual metabolites can
identify serum metabolites as potential biomarkers for the early detection of lung
cancer. In this study, we propose to use a global metabolomic profiling platform,
which can measure hundreds of metabolites simultaneously, to provide a
comprehensive assessment of metabolites from serum of NSCLC patients
compared to paired healthy control subjects. These metabolomic profiles can
guide the identification of novel biomarkers for early detection of NSCLC.

1.8.2. Hypothesis II: Pre-treatment clinical laboratory tests indicative of metabolic
status are associated with survival in NSCLC patients, which could serve
as biomarkers for clinical outcome in NSCLC patients.
Survival time varies significantly among early stage or late stage NSCLC
patients. Clinically relevant biomarkers that predict prognosis and survival time
are urgently needed to personalize treatment regimens and manage expectations.
Patients’ pre-treatment clinical laboratory test levels are reflective of
18

patient-related and environmental factors. Serum pre-treatment laboratory test
levels have long been reported to be prognostic factors for SCLC (36). Therefore,
we hypothesized that pre-treatment laboratory test levels that indicate metabolic
status are associated with NSCLC patients’ survival, and could be utilized as
biomarkers for NSCLC clinical outcome prediction.
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Chapter 2. Materials and Methods
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2.1. Study Population and Data Collection
MD Anderson Case-Control Population in Metabolomics Study
The lung cancer cases and control subjects were from an ongoing lung
cancer case-control study at the University of Texas MD Anderson Cancer Center
(37). Cases were newly diagnosed, histologically confirmed non-small cell lung
cancer (NSCLC) patients previously untreated with chemotherapy or radiotherapy
at MD Anderson Cancer Center. There were no restrictions on age, sex, or
ethnicity at study recruitment. Early stage NSCLC included stages I and II, while
late stage NSCLC included stages III and IV. The controls were recruited in the
Kelsey Seybold Clinics, Houston’s largest private multispecialty group practice
with 18 clinics in the Houston metropolitan area. The control subjects were
healthy individuals without prior history of cancer (except for non-melanoma skin
cancer). To control for the confounding effect of ethnicity, we only included
Caucasians in this study. Twenty each of controls, early-stage, and late-stage
NSCLC cases (hereafter referred to as “trio”) were used for metabolomic profiling.
Promising metabolites identified from this profiling were examined in two
additional case-control samples, consisting of 50 trios and 123 trios, respectively
(Figure 3). All participants completed an in-person interview administered by MD
Anderson staff interviewers using a structured questionnaire. Demographic
characteristics, smoking history, family history of cancer, environmental
exposures and other epidemiologic data were collected and recorded. At the end
of the interview, each participant donated 40ml blood sample for molecular
analysis.
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All patients and controls gave written informed consent before participation,
and the study was approved by the Institutional Review Boards of the MD
Anderson Cancer Center and the Kelsey Seybold Clinics.
The Taiwanese Prospective Cohort Population for Metabolomic Validation
The Taiwanese prospective cohort population was obtained from a
standard medical screening program conducted by the MJ Health Management
Institution at Taiwan (hereon referred to as “MJ”). From 1994 to 2008, a total of
435,985 subjects aged 20 years and older, free of cancer at baseline, were
recruited. Median follow-up time for the cohort is 8 years (interquartile range: 5-11
years) for male participants and 9 years (interquartile range: 5-11 years) for
female participants. All participants completed a self-administered questionnaire
covering demographic characteristics and health history. All subjects underwent a
series of medical tests for blood, urine, physical examination, body
measurements and functional tests, including testing for anthropometric
measurements (e.g., height, weight, waist circumference, hip circumference, body
fat percentage, etc.), blood pressure, pulse rate and respiration rate. Overnight
fasting blood was analyzed for a standard panel, including hemogram and testing
for blood sugar, liver function, renal function, thyroid function, blood lipids and
blood grouping. The cohort members were followed through 2008 for cancer and
vital status, which were assessed by linkage of the individual ID to the National
Cancer Registry and National Death file.
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All participants signed an informed consent. The studies were approved by
the Institutional Review Boards of the University of Texas MD Anderson Cancer
Center and National Health Research Institutes, Taiwan.
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Figure 3. Study design of lung cancer metabolomic profiling and validation
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MD Anderson Lung Cancer Patient Population for Lung Cancer Clinical Outcome
This study was conducted in 2,806 patients with newly diagnosed,
histologically confirmed NSCLC recruited at the University of Texas MD Anderson
Cancer Center. None of the study subjects had undergone chemotherapy or
radiotherapy treatment before study enrollment. There were no restrictions on age,
sex, or ethnicity at recruitment. Excluding 131 patients with unknown clinical stage
information, there were 2,675 patients remaining for analysis. Early stage NSCLC
included stages I and II patients, while advanced stage NSCLC included stages III
and IV patients. All participants completed an in-person interview by trained MD
Anderson Cancer Center staff using a structured questionnaire. Demographic
characteristics, smoking history, family history of cancer, and exposure data were
collected. After the interview, each participant donated 40 ml blood sample for
molecular analysis. Clinical and follow-up data were extracted from medical
charts by trained medical staff. Pretreatment serum levels of albumin, alkaline
phosphatase, alanine aminotransferase, total bilirubin, glucose, lactate
dehydrogenase and total protein were measured as part of a standard battery of
tests evaluating patients’ overall metabolic status. The normal ranges of the tests
were based on standard laboratory norms. All study subjects had their blood
drawn and laboratory tests evaluated no earlier than 30 days before diagnosis
and before implementation of any treatment.
All patients signed written informed consent before participation, and the
study was approved by the Institutional Review Board of the University of Texas
MD Anderson Cancer Center.
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2.2. Global Metabolomic Profiling
The metabolomic profiling analysis of all samples was carried out by
Metabolon, Inc (Durham, NC) using the following general protocol described
previously (38). Briefly, this process involved: sample extraction, separation,
detection, spectral analysis, data normalization, delineation of class-specific
metabolites and pathway mapping. All samples were randomized prior to mass
spectrometric analyses to avoid any experimental drifts. A number of internal
standards, including injection standards, process standards, and alignment
standards were used to assure QA/QC targets were met and to control for
experimental variability. Samples were kept frozen until assays were ready to be
performed. The samples were extracted and divided into three equal portions for
analysis on one of the three platforms: ultrahigh performance liquid
chromatography/tandem mass spectrometry (UHLC/MS/MS2) optimized for basic
species, UHLC/MS/MS2 optimized for acidic species, and gas
chromatography/mass spectrometry (GC/MS). For UHLC/MS/MS2 analysis, two
aliquots were processed with one using acidic positive ion optimized conditions
and the other using basic negative ion optimized conditions in two independent
injections using separate dedicated columns. The platform includes a Waters
ACQUITY ultra-performance liquid chromatography (UPLC) system (Waters,
Millford, MA) and an LTQ mass spectrometer (Thermo Fisher Scientific, Inc.,
Waltham, MA) comprised of electrospray ionization (ESI) source and linear
ion-trap (LIT) mass analyzer. The MS instrument scans 99-1000 m/z and
alternates between MS and MS2 scans using dynamic exclusion with
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approximately 6 scans per second. For GC/MS analysis, one aliquot was used
and separated on a 5% phenyldimethyl silicone column with helium as the carrier
gas and a temperature ramp from 60°C to 340°C. The platform includes a
Thermo-Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer
that uses electron impact ionization (Thermo Fisher Scientific, Inc.) and has a
50-750 atomic mass unit scan range. Metabolites were identified by automated
comparison of the ion features in the experimental samples to the metabolomic
library of chemical standard entries using software developed at Metabolon (39).
Known chemical entities were mapped to the metabolomic library entries of
purified standards. Identification of additional entities was based on the virtue of
their recurrent nature (both chromatographic and mass spectral).
2.3. Quantification of individual metabolites
Gamma-glutamylalanine and bilirubin standard powders were purchased
from Sigma-Aldrich (St. Louis, MO). Individual metabolite quantification was done
at Texas Southern University (Houston, TX). Quantification of individual
metabolite in serum was determined by LC-MS/MS methods using a 3200
QTRAP® MS/MS coupled by an Agilent 1200 Series HPLC system. Standard
curves for each compound were constructed by spiking known amount of the
standard to a series of blank plasma (Gulf Coast Blood Bank, Houston, TX). For
the determination of λ-glutamylalanine, aliquot of serum samples (50 µL) was
mixed with 500 µL of a 2:1 ratio (v/v) solution of methanol/acetone containing
etravirine as an internal standard. After a brief vortex and centrifugation, the
supernatant was transferred to a 12x75 mm glass tube where it was dried under
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pure nitrogen. The residual was then reconstituted with 100 µL of a 1:1 (v/v)
solution of methanol/water before HPLC injection. Gamma-glutamylalanine and
the internal standard were separated on a reverse phase XTerra MS-C18 (2.1 x
50mm, 3.5 μm) column. The mobile phases consisted of a 0.5 mM ammonium
acetate aqueous solution (mobile phase A) and a 100% acetonitrile solution
(mobile phase B). A gradient elution starting with 95% mobile phase A at a flow
rate of 200 µL/min was applied to achieve retention time of 0.69 min and 4.3 min
for λ-glutamylalanine and the internal standard, respectively. For the
determination of bilirubin, aliquot of serum samples (50 µL) was mixed with 250
µL of methanol containing etravirine as an internal standard. After a brief vortex
and centrifugation, the supernatant was injected directly onto the HPLC system.
Bilirubin and the internal standard were separated on a reverse phase XTerra
MS-C18 (2.1 x 50mm, 3.5 μm) column. The mobile phases consisted of a 2 mM
ammonium acetate aqueous solution adjusted to pH 7.8 by ammonium hydroxide
(mobile phase A) and a 98% methanol solution containing 2% (v/v) of a 2 mM
ammonium acetate (mobile phase B). A gradient elution starting with 70% mobile
phase A at a flow rate of 200 µL/min was applied to achieve retention time of 5.6
min and 5.8 min for bilirubin and the internal standard, respectively.
Mass spectrometric detection was performed on a 3200 QTRAP® (AB
Sciex, Foster City, CA, USA), a hybrid triple quadrupole linear ion trap equipped
with a TurboIonspray ion source. A Parker Balston Source 5000Tri Gas generator
was used to generate pure nitrogen. The mass spectrophotometer was set at the
negative mode. The transition ions were detected using multiple reaction
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monitoring from a specific parent ion transition to product ion for λ-glutamylalanine
(m/z 217128), bilirubin (583.4285), and etravirine (432.9141.6). Peak areas
and other compound parameters were determined by Analyst R software, version
1.5. Standard curve ranges are 25 – 500 ng/mL and 500 – 10,000 ng/mL for
λ-glutamylalanine and bilirubin, respectively.
2.4. Statistical Analyses
Lung Cancer Metabolomic Profiling Study
In the case-control analysis, the Pearson χ2 test was used to examine the
differences in sex and smoking status between cases and controls. Student’s t
test was used to test for differences in age and pack-years of smoking as
continuous variables. For the metabolomic profiling assay, missing metabolite
measurements, which were due to levels below detection limits, were imputed
with the compound minimum (minimum value imputation). Only metabolites with
detectable expression in at least 80% of the samples were analyzed.
Nonparametric two-sided Wilcoxon rank-sum tests were used to analyze the
differences of metabolite levels between cases and controls for both metabolomic
profiling and individual metabolite validation assay. Nonparametric trend test was
used to analyze the trend across normal controls, early stage lung cancer and late
stage lung cancer cases for both metabolomic profiling and individual metabolite
validation assay. Spearman’s correlation test was used to assess the correlation
between the two values measured with metabolomic profiling and individual
metabolite assay with LC-MS/MS.
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For the MJ cohort, serum total bilirubin levels were divided into three
groups with equal tertile in men or women. Cox proportional hazard models were
used to assess the association of serum total bilirubin levels with lung cancer
incidence or mortality rate using the highest tertile category of bilirubin levels (>1
mg/dL for men and >0.82 mg/dL for women) as reference. For lung cancer
incidence, the event time was from the date of recruitment to the end of follow-up,
or the date of lung cancer identification if earlier. For lung cancer mortality, the
event time was from the date of recruitment to the end of follow-up, or the date of
death due to lung cancer if earlier. Hazard ratios were adjusted for age,
educational level (middle school or lower, high school, junior college, or college or
higher), body mass index (BMI) and pack-years of smoking in a multivariable
model with continuous variables whenever appropriate. The proportional hazards
assumption was assessed by plotting Schoenfeld residuals versus time and
examining their correlation. Two-way interactions between smoking status and
serum total bilirubin levels were assessed for lung cancer incidence and mortality
in men and women. Non-parametric trend tests were used to analyze the trend of
serum total bilirubin levels across each characteristic group of the cohort (e.g.,
age, BMI, etc). All statistical tests were two-sided with the threshold for
significance set at 0.05. Statistical analyses were performed using STATA 10.0
(StataCorp, College Station, TX).
Clinical Laboratory Tests and Lung Cancer Clinical Outcome Study
The primary endpoint for this study was overall survival. Secondary
endpoints for early stage NSCLC patients were recurrence and progression.
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Survival time was calculated from the date of diagnosis to the date of death or last
patient follow-up. Chi-square test was used to assess differences in patient
characteristics. Multivariable Cox proportional hazards model was used to assess
the effect of each pretreatment serum laboratory test level on 2-year or 5-year
survival, adjusted for age, sex, smoking status, clinical stage, and treatment
regimen. Kaplan-Meier survival analysis was used to estimate survival, and
log-rank tests were used to assess the differences in overall survival for each
laboratory test. The cumulative effects of multiple unfavorable laboratory test
levels were evaluated for the three tests that showed statistical significance in the
main analysis (i.e., P < 0.05). The lab-test based risk score for each patient was
derived by linear combination of the product of reference-normalized expression
level of each laboratory test by its Cox regression corresponding coefficient (21).
All patients were dichotomized by the median risk score, and individuals with a
risk score higher or lower than the median were classified as high or low risk
groups, respectively. A P value less than 0.05 was considered significant in all
statistical analyses. All statistical analyses were conducted using STATA software,
version 10 (StataCorp, College Station).
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Chapter 3. Results and Discussion
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3.1. Lung Cancer Metabolomic Profiling Study
3.1.1. Characteristics of the study population
In the case-control studies, the lung cancer cases and healthy controls
were all Caucasians, matched on age and gender (Table 1). The Taiwanese MJ
cohort consisted of 425,660 subjects (202,902 men and 222,758 women) aged 20
years and older (Table 2). Median follow-up time for this cohort was 8 years
(interquartile range [IQR], 5-11 years) for men and 9 years (IQR, 5-11 years) for
women, which yielded a total of more than 3.4 million person-years of follow-up.
The average age at testing was 41 for both men and women. Median total
bilirubin level was 0.87 mg/dL (IQR, 0.68-1.11 mg/dL) in men and 0.7 mg/dL (IQR,
0.56-0.9 mg/dL) in women. Serum total bilirubin levels were higher in men than in
women, which were consistent with previous studies (40, 41). Selected
demographic characteristics and exposures of the cohort participants are shown
in Table 2, presented by gender and tertiles of bilirubin level (<0.75, 0.75-1 and >1
mg/dL for men and <0.61, 0.61-0.82 and >0.82 mg/dL for women). Distribution of
serum total bilirubin levels among the participants in the cohort is shown in Figure
3. Among male participants in the cohort, over half (52.1%) were smokers, with 25%
of them being heavy smokers of ≥30 pack-years. In contrast, only 17,123 (8.3%)
female participants were smokers, with 1,327 (8.3%) of them being heavy
smokers. During the follow-up, there were 809 incident lung cancer cases and
614 lung cancer deaths among the males, and 524 lung cancer cases and 330
deaths among the females.
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Table 1. Selected host characteristics of three case-control populations

Characteristics

Phase I (N=60)
Cases

Phase II (N=150)
Cases

Controls

Controls

P
(N=50)

61 (12)

59 (12)

40 (40.0)

20 (40.0)

27 (67.5)

12 (60.0) 0.57 60 (60.0)

30 (60.0)

Non-smoker

6 (15.0)

7 (35.0)

16 (32.0)

Smoker

34 (85.0)

13 (65.0) 0.19 79 (79.0)

(N=20)

62 (11)

59 (10)

Male

13 (32.5)

8 (40.0)

Female

Cases

Controls

(N=246)

(N=123)

64 (10)

64 (10)

P
(N=100)

(N=40)

Phase III (N=369)

P

Age
Mean (SD), y

0.38

0.43

0.82

Sex, No. (%)
174 (70.7) 87 (70.7)
1

72 (29.3)

36 (29.3)

37 (15.0)

34 (27.6)

1

Smoking status, No. (%)

Pack year, Mean (SD)

48.0 (30.7)

21 (21.0)

34 (68.0) 0.14 209 (85.0) 89 (72.4)

0.009

54.1 (42.3) 0.59 44.7 (31.5) 48.5 (32.9) 0.57 52.1 (32.1) 33.9 (25.9) <0.001
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Table 2. Characteristics of the participants in the prospective cohort by gender and serum total bilirubin levels a
Characteristics

Men (N = 202,902), N (%)
Total

Women (N = 222,758), N (%)

Total bilirubin level (mg/dL)
>1

0.75-1

<0.75

Total

Total bilirubin level (mg/dL)
>0.82

0.61-0.82

<0.61

Total

202,902

67,841 (33.4)

65,540 (32.3)

69,521 (34.3)

222,758

75,189 (33.8)

72,207 (32.4)

75,362 (33.8)

Age (y), mean (SD)

41 (14)

40 (14)

42 (14)

41 (14)

41 (14)

41 (14)

42 (14)

41 (13)

20-39

112,584 (55.5)

39,399 (35.0)

35,270 (31.3)

37,915 (33.7)

119,946 (53.9)

41,854 (34.9)

37,510 (31.3)

40,582 (33.8)

40-59

63,447 (31.3)

19,927 (31.4)

21,201 (33.4)

22,319 (35.2)

76,087 (34.2)

23,908 (31.4)

25,500 (33.5)

26,679 (35.1)

26,871 (13.2)

8,515 (31.7)

9,069 (33.8)

9,287 (34.6)

26,725 (12)

9,427 (35.3)

9,197 (34.4)

8,101 (30.3)

23.9 (3.4)

23.5 (3.3)

23.9 (3.3)

24.2 (3.4)

22.3 (3.6)

21.8 (3.5)

22.3 (3.6)

22.8 (3.7)

<25

134,591 (66.4)

47,499 (35.3)

43,264 (32.1)

43,828 (32.6)

176,567 (79.3)

62,056 (35.2)

57,139 (32.4)

57,372 (32.5)

25-29.9

59,734 (29.5)

18,062 (30.2)

19,565 (32.8)

22,107 (37.0)

38,454 (17.3)

11,040 (28.7)

12,660 (32.9)

14,754 (38.4)

8,516 (4.2)

2,264 (26.6)

2,696 (31.7)

3,556 (41.8)

7,689 (3.5)

2,080 (27.1)

2,394 (31.1)

3,215 (41.8)

Middle school or lower

40,499 (20.6)

12,823 (31.7)

13,379 (33.0)

14,297 (35.3)

70,385 (32.6)

23,109 (32.8)

23,546 (33.5)

23,730 (33.7)

High school

45,601 (23.2)

14,665 (32.2)

14,693 (32.2)

16,243 (35.6)

54,124 (25.1)

17,238 (31.9)

17,186 (31.8)

19,700 (36.4)

Junior college

45,367 (23.1)

15,705 (34.6)

14,526 (32.0)

15,136 (33.4)

42,941 (19.9)

15,153 (35.3)

13,525 (31.5)

14,263 (33.2)

College or higher

64,987 (33.1)

22,603 (34.8)

20,844 (32.1)

21,540 (33.2)

48,400 (22.4)

17,428 (36.0)

15,692 (32.4)

15,280 (31.6)

Non-smoker

92,864 (47.9)

35,175 (37.9)

30,188 (32.5)

27,501 (29.6)

188,685 (91.7)

64,488 (34.2)

61,534 (32.6)

62,663 (33.2)

Smoker

101,092 (52.1)

29,632 (29.3)

32,451 (32.1)

39,009 (38.6)

17,123 (8.3)

4,891 (28.6)

5,228 (30.5)

7,004 (40.9)

<30 pack-years

72,153 (74.9)

21,843 (30.3)

23,084 (32.0)

27,226 (37.7)

14,662 (91.7)

4,303 (29.4)

4,403 (30.0)

5,956 (40.6)

≥30 pack-years

24,146 (25.1)

6,269 (26.0)

7,777 (32.2)

10,100 (41.8)

1,327 (8.3)

279 (21)

434 (32.7)

614 (46.3)

Lung cancer incidence

809 (0.4)

215 (26.6)

270 (33.4)

324 (40.1)

524 (0.2)

155 (29.6)

187 (35.7)

182 (34.7)

Lung cancer mortality

614 (0.3)

147 (23.9)

214 (34.9)

253 (41.2)

330 (0.2)

107 (32.4)

115 (34.9)

108 (32.7)

≥60
2

BMI (kg/m ), mean (SD)

≥30
Educational levels

Smoking status

a

Percentage may not total 100 because of rounding.
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Figure 4. Distribution of serum total bilirubin levels among male (A) and
female (B) participants in the MJ cohort.
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3.1.2. Global metabolomic profiling of lung cancer
Serum global metabolomic profiles of 40 lung cancer cases and 20 healthy
controls (20 trios) were assessed in the initial case-control study and a total of 403
named metabolites were identified. After exclusion of metabolites detected in less
than 80% of samples, 306 (76%) metabolites remained. These metabolites were
mapped to 8 super-pathways and 61 sub-pathways (Appendix B). Among these,
24 metabolites exhibited significantly differential expression between lung cancer
cases and healthy controls (Table 3). Furthermore, 29 metabolites exhibited a
significant trend of expression when comparing normal controls, early and late
stage cases, 12 of which had P for trend values < 0.01 (Table 4).
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Table 3. Metabolites with significantly differential expression between lung
cancer cases and healthy controls in metabolomic profiling.
Relative Expression Value
Metabolite

Controls, Mean (SD)

Cases, Mean (SD)

N=20

N=40

2-pyrrolidinone

184,592 (67,739)

120,309 (38,326)

<0.001

λ-glutamylalanine

73,251 (15,477)

55,538 (14,767)

<0.001

prolylhydroxyproline

99,837 (32,892)

147,019 (85,297)

0.003

149,185 (191,016)

52,631 (57,472)

0.004

citrate

4,436,480 (1,350,699)

3,526,780 (910,400)

0.008

inosine

6,089 (7,742)

15,731 (25,092)

0.008

18,830 (13,613)

25,914 (12,996)

0.009

379,215 (354,715)

186,720 (262,879)

0.01

xylonate

34,788 (19,194)

48,479 (21,691)

0.01

ribose

65,583 (26,471)

92,345 (56,000)

0.02

pyroglutamine*

83,523 (47,468)

120,072 (72,884)

0.02

2-hydroxyglutarate

73,643 (22,606)

59,895 (21,528)

0.02

bilirubin

42,818 (37,297)

28,382 (23,597)

0.03

326,254 (110,182)

460,063 (260,002)

0.03

serotonin (5HT)

41,042 ( 26,983)

58,634 (33,030)

0.03

alpha-tocopherol

1,275,449 (447,775)

16,23,417 (872,291)

0.03

acetylcarnitine (C2)

1,127,480 (371,971)

1,292,182 (307,364)

0.03

caproate (6:0)

55,317 ( 13,834)

49,014 (15,451)

0.03

gamma-CEHC

9,740 (5,548)

6,694 (3,971)

0.04

7,266,894 (1,210,393)

6,764,267 (1,438,869)

0.04

nonadecanoate (19:0)

34,914 (20,482)

42,556 (19,167)

0.04

citrulline

192,653 (61,750)

157,052 (45,065)

0.05

3,537,910 (6,648,727)

5,629,617 (7,296,060)

0.05

83,975 (37,169)

65,360 (37,853)

0.05

P Value

bradykinin, des-arg(9)

octadecanedioate (C18)
ascorbate (Vitamin C)

1-docosahexaenoyl-GPC* (22:6)*

tryptophan

3-hydroxybutyrate (BHBA)
lathosterol
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Table 4. Metabolites with significant trend of expression comparing normal
controls, early stage and late stage cases in metabolomic profiling
Relative Expression Value
Controls

Early stage cases

Late stage cases

Mean (SD)

Mean (SD)

Mean (SD)

N=20

N=20

N=20

73,251 (15,477)

58,721 (15,063)

52,355 (14,121)

<0.0001

bradykinin,,des-arg(9)

149,185 (191,016)

72,002 (72,510)

33,260 (27,061)

0.0004

2-pyrrolidinone

184,592 (67,739)

119,052 (40,019)

121,566 (37,554)

0.0007

ribose

65,583 (26,471)

85,819 (74,815)

98,871 (27,388)

0.0008

prolylhydroxyproline

99,837 (32,892)

145,811 (109,956)

148,228 (53,298)

0.001

379,215 (354,715)

241,922 (323,738)

131,519 (175,005)

0.003

pyroglutamine

83,523 (47,468)

94,411 (38,913)

145,732 (89,461)

0.004

bilirubin

42,818 (37,297)

34,885 (27,919)

21,879 (16,568)

0.005

4,436,480 (1,350,699)

3,703,495 (826,483)

3,350,065 (975,942)

0.006

dimethylglycine

374,999 (117,999)

394,627 (129,304)

519,430 (162,458)

0.007

λ-glutamylglutamine

158,358 (41,747)

147,878 (48,266)

115,265 (50,958)

0.009

allantoin

45,083 (18,638)

62,444 (60,083)

105,248 (75,072)

0.009

xylonate

34,788 (19,194)

44,653 (14,651)

52,306 (26,838)

0.013

citrulline

192,653 (61,750)

168,397 (36,799)

145,707 (50,432)

0.015

taurochenodeoxycholate

35,192 (25,112)

36,905 (29,972)

107,807 (157,690)

0.015

801,195 (206,034)

880,737 (261,529)

1,014,750 (243,831)

0.015

octadecanedioate (C18)

18,830 (13,613)

24,281 (10,670)

27,548 (15,075)

0.019

C-glycosyltryptophan*

30,314 (5,611)

31,348 (7,797)

42,725 (18,271)

0.021

caproate (6:0)

55,317 (13,834)

51,113 (14,652)

46,915 (16,312)

0.023

2-hydroxypalmitate

273,748 (54,880)

284,755 (59,536)

315,180 (67,137)

0.024

N-acetylalanine

11,056 (1,936)

11,228 (1,837)

13,237 (3,363)

0.024

N-acetylneuraminate

93,377 (30,573)

93,898 (46,055)

184,215 (142,088)

0.025

beta-hydroxyisovalerate

23,341 (16,904)

20,560 (13,029)

32,634 (23,122)

0.027

7,826,930 (1,625,275)

8,346,346 (2,541,086)

9,321,622 (2,069,754)

0.027

2-ethylhexanoic,acid

837,760 (370,924)

808,623 (287,933)

622,298 (400,523)

0.027

bilirubin (E,E)*

545,806 (488,517)

595,041 (394,994)

333,095 (247,461)

0.036

benzoate

901,738 (163,812)

929,460 (118,775)

830,883 (136,694)

0.043

taurolithocholate,3-sulfate

22,282 (14,217)

27,824 (26,186)

41,376 (28,524)

0.044

glycocholate

74,886 (58,775)

81,622 (98,815)

144,855 (155,358)

0.048

Metabolite

λ-glutamylalanine

ascorbate (Vitamin,C)

citrate

betaine

isoleucine
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P Value

3.1.3. Target validation of individual metabolites
Metabolites exhibiting a significant trend in levels from normal individuals
to early and late stage patients are potential biomarkers for the detection and
prognosis of lung cancer. Of the 29 metabolites with significant trends, bilirubin
caught our most interest given its potent endogenous cytoprotective properties
and more importantly, its inverse association with cardiovascular disease and
respiratory disease in previous reports (41-44). Therefore, we selected bilirubin
and λ-glutamylalanine, which showed the most significant trend from metabolomic
profiling for further validation. We developed standard LC/MS-MS assays for
these metabolites and used these assays to measure their levels in the 20 trios of
cases and controls from phase I of the case-control study; we found excellent
correlation with metabolomic profiling data. We further examined levels of bilirubin
and λ-glutamylalanine in additional 50 trios of serum samples (phase II) and 123
trios of serum samples (phase III) from controls and early and late-stage patients
(Table 5). Through this process, bilirubin emerged as a metabolite that
consistently showed a statistically significant trend in all three sets of trio data.
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Table 5. Levels of the two individual metabolites of interest measured with
LC/MS-MS in the three case-control studies
Metabolite

Expression Level, Mean (SD)
Controls

Early stage

P Value

Late stage

Phase I (N=60)

λ-glutamylalanine (ng/mL)
Bilirubin (μg/mL)

(N = 20)

(N = 20)

(N = 20)

98.28 (35.01)

68.06 (42.58)

73.96 (32.82)

0.03

2.81 (1.43)

2.12 (1.29)

1.54 (0.84)

0.004

Phase II (N=150)

λ-glutamylalanine (ng/mL)
Bilirubin (μg/mL)

(N = 50)

(N = 50)

(N = 50)

113.57 (43.01)

107.55 (42.68)

101.28 (36.3)

0.1

3.10 (1.81)

2.78 (1.54)

1.91 (1.03)

0.0001

Phase III (N=369)

λ-glutamylalanine (ng/mL)
Bilirubin (μg/mL)

(N = 123)

(N = 123)

(N = 123)

183.17 (81.69)

181.17 (104.05)

144.04 (78.6)

0.0002

2.69 (1.77)

2.56 (1.73)

2.25 (1.47)

0.02
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3.1.4. Validation of bilirubin as a lung cancer marker in a large cohort
Since bilirubin is a routine blood test in health examination, we next
assessed the association of blood test serum total bilirubin levels with lung cancer
incidence and mortality using a large prospective cohort in Taiwan. In this cohort,
younger age, lower BMI, never smoking status, lower systolic blood pressure and
higher education status were all significantly associated with higher bilirubin levels
in men (Supplementary Table 5). Similar associations were also observed in
women. Total incidence rate for lung cancer was 5.64 (95 % CI, 5.26-6.05) per
10,000 person-years in men and 3.17 (95 % CI, 2.90-3.46) in women. Total lung
cancer specific mortality rate was 3.88 (95% CI, 3.58-4.20) per 10,000
person-years in men and 1.85 (95% CI, 1.66-2.06) in women. Lower bilirubin level
was associated with significantly higher rates of both lung cancer incidence and
lung cancer specific mortality in men but not women. The incidence rate of lung
cancer per 10,000 person-years in men was 4.27 (95% CI, 3.71-4.90) in the
highest tertile of bilirubin level (>1 mg/dL) compared to 6.93 (95% CI, 6.20-7.75)
in the lowest tertile (<0.75 mg/dL), which translated to a 52% increase in lung
cancer incidence for the low bilirubin group (P < 0.001). The corresponding lung
cancer specific mortality rate in men was 2.70 (95% CI, 2.30-3.17) in the highest
tertile compared to 4.88 (95% CI, 4.32-5.52) in the lowest tertile, a 71% increase
in lung cancer specific mortality for the low bilirubin group (P<0.001) (Table 10).
As expected, there was a strong dose response relationship between lung
cancer risk/mortality and pack-years of smoking or smoking intensity in this cohort
(Tables 6 and 7). Furthermore, among males, using non-smokers with the highest
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tertile of bilirubin levels (>1 mg/dL) as reference, smokers in the lowest tertile of
bilirubin levels (<0.75 mg/dL) had a 2.86-fold increased risk of developing lung
cancer (Table 6). Smokers with <30 and ≥30 pack-years of smoking had HRs of
1.40 and 4.14 respectively (Table 6 and Fig. 4A). Similarly, smokers in the lowest
tertile of bilirubin levels who smoked <10, 10-19 and ≥20 cigarettes per day had
HRs of 1.85, 2.70 and 4.32, respectively (Table 6 and Fig. 4B). Similar results
were found for lung cancer mortality (Table 7, Fig. 5A and 5B). In contrast, among
females, lower serum bilirubin levels were not significantly associated with lung
cancer incidence or mortality overall, in female smokers or in female non-smokers
(Tables 8 and 9). Table 10 presents the rates of lung cancer incidence and
mortality stratified by tertiles of serum bilirubin levels and corresponding risk
estimates. We plotted the lung cancer incidence rates against subgroups of
bilirubin levels and introduced a best-fit model. Those with bilirubin levels <0.42
mg/dL showed more than 80% increase in lung cancer incidence rate (6.1 vs 3.27
per 100,000 person-years, Figure 4A) and over two folds increase in mortality rate
(4.09 vs 1.94 per 100,000 person-years, Figure 4B) compared to the subgroup
with bilirubin levels >1.62 mg/dL.
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Table 6. Relationship among smoking quantity, bilirubin levels and risk for lung cancer incidence by smoking
status among male participants in the prospective cohort study
Men (N=202,902)
Total

Total bilirubin level (mg/dL)
>1

No. of

No. of
HRa (95% CI)

No.

0.75-1

incidence

No. of
HRa (95% CI)

No.

<0.75

incidence

No. of
HRa (95% CI)

No.

HRa (95% CI)

No.

incidence

incidence

Non-smoker

92,864

156

1 (Ref)

35,175

64

1 (Ref)

30,188

50

0.87 (0.59-1.27)

27,501

42

0.85 (0.56-1.27)

Total smokers

101,092

603

2.64 (2.19-3.18)

29,632

139

1.84 (1.35-2.51)

32,451

202

2.38 (1.77-3.19)

39,009

262

2.86 (2.15-3.81)

<30 pack-years

72,153

123

1.31 (1.02-1.69)

21,843

27

0.80 (0.50-1.29)

23,084

47

1.37 (0.92-2.03)

27,226

49

1.40 (0.94-2.07)

≥30 pack-years

24,146

454

4.01 (3.27-4.91)

6,269

108

3.14 (2.25-4.36)

7,777

145

3.48 (2.54-4.77)

10,100

201

4.14 (3.06-5.60)

<10

31,520

106

1.55 (1.20-2.01)

10,602

23

0.96 (0.58-1.57)

10,270

37

1.39 (0.91-2.13)

10,648

46

1.85 (1.24-2.74)

10-19

38,866

261

2.71 (2.19-3.34)

11,031

62

1.97 (1.36-2.84)

12,557

91

2.58 (1.84-3.60)

15,278

108

2.70 (1.95-3.72)

≥20

26,879

221

4.29 (3.46-5.33)

6,759

52

3.39 (2.31-4.96)

8,374

70

3.72 (2.61-5.30)

11,746

99

4.32 (3.11-5.99)

Pack-year

# of Cigarettes per day

a

Adjusted for age, educational level and body mass index
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Table 7. Relationship among smoking quantity, bilirubin levels and lung cancer mortality by smoking status
among male participants in the prospective cohort study
Men (N = 202,902)
Total bilirubin level (mg/dL)
Total
>1
No.

No. of

HRa (95% CI)

No.

No. of

0.75-1
HRa (95% CI)

No.

mortality

mortality

No. of

HRa (95% CI)

<0.75
No.

mortality

No. of

HRa (95% CI)

mortality

Non-smoker

92,864

98

1 (Ref)

35,175

36

1 (Ref)

30,188

34

1.04 (0.65-1.66)

27,501

28

0.99 (0.60-1.63)

Total smokers

101,092

478

3.24 (2.60-4.05)

29,632

104

2.39 (1.63-3.50)

32,451

165

3.28 (2.28-4.72)

39,009

209

3.96 (2.77-5.65)

<30 pack-years

72,153

90

1.62 (1.20-2.18)

21,843

14

0.80 (0.43-1.48)

23,084

39

2.08 (1.31-3.30)

27,226

37

2.01 (1.26-3.20)

≥30 pack-years

24,146

370

4.78 (3.77-6.05)

6,269

89

4.18 (2.81-6.22)

7,777

119

4.56 (3.11-6.69)

10,100

162

5.52 (3.81-7.99)

<10

31,520

84

1.95 (1.45-2.62)

10,602

14

1.05 (0.56-1.94)

10,270

29

1.91 (1.17-3.14)

10,648

41

2.88 (1.83-4.52)

10-19

38,866

211

3.38 (2.65-4.32)

11,031

48

2.65 (1.71-4.09)

12,557

77

3.65 (2.45-5.45)

15,278

86

3.75 (2.53-5.55)

≥20

26,879

172

5.16 (4.01-6.65)

6,759

42

4.64 (2.96-7.27)

8,374

55

4.95 (3.24-7.57)

11,746

75

5.74 (3.85-8.56)

Pack-year

# of Cigarettes per day

a

Adjusted for age, educational level and body mass index
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Table 8. Relationship among smoking quantity, bilirubin levels and risk for lung cancer incidence by smoking
status among female participants in the prospective cohort study

Women (N = 222,758)
Total

Total bilirubin level (mg/dL)
>0.82

No. of
No.

HRa (95% CI)

No. of
No.

incidence

0.61-0.82
HRa (95% CI)

No. of
No.

incidence

HRa (95% CI)

<0.61
No. of
No.

incidence

HRa (95% CI)

incidence

Non-smoker

188,685

435

1 (Ref)

64,488

127

1 (Ref)

61,534

157

1.35 (1.06-1.73)

62,663

151

1.36 (1.06-1.74)

Total smokers

17,123

37

1.23 (0.87-1.74)

4,891

11

1.55 (0.81-2.98)

5,228

10

1.23 (0.64-2.35)

7,004

16

1.68 (0.99-2.86)

<30 pack-years

14,662

13

0.61 (0.34-1.08)

4,303

5

0.86 (0.32-2.34)

4,403

2

0.38 (0.09-1.56)

5,956

6

0.97 (0.43-2.22)

≥30 pack-years

1,327

21

2.84 (1.82-4.43)

279

4

3.16 (1.16-8.57)

434

7

3.25 (1.51-6.99)

614

10

3.88 (2.02-7.43)

<10

10,403

16

0.89 (0.53-1.49)

3,237

8

1.75 (0.81-3.75)

3,201

2

0.44 (0.11-1.77)

3,965

6

1.18 (0.52-2.70)

10-19

4,054

12

1.54 (0.86-2.73)

1,004

3

2.03 (0.64-6.40)

1,210

2

0.93 (0.23-3.76)

1,840

7

2.61 (1.21-5.61)

≥20

1,693

8

3.02 (1.50-6.08)

382

0

N/A

475

6

8.91 (3.91-20.29)

836

2

2.03 (0.50-8.21)

Pack-year

# of Cigarettes per day

a

Adjusted for age, educational level and body mass index
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Table 9. Relationship among smoking quantity, bilirubin levels and lung cancer mortality by smoking status
among female participants in the prospective cohort study

Women (N = 222,758)
Total bilirubin level (mg/dL)
Total
>0.82
No.

No. of

HRa (95% CI)

No.

No. of

0.61-0.82

HRa (95% CI)

No.

mortality

mortality

No. of

HRa (95% CI)

<0.61
No.

mortality

No. of

HRa (95% CI)

mortality

Non-smoker

188,685

261

1 (Ref)

64,488

85

1 (Ref)

61,534

90

1.10 (0.82-1.48)

62,663

86

1.10 (0.81-1.49)

Total smokers

17,123

31

1.69 (1.16-2.46)

4,891

9

1.89 (0.94-3.78)

5,228

9

1.50 (0.75-3.00)

7,004

13

1.88 (1.04-3.39)

<30 pack-years

14,662

8

0.67 (0.33-1.35)

4,303

3

0.91 (0.29-2.88)

4,403

1

0.27 (0.04-1.96)

5,956

4

0.93 (0.34-2.55)

≥30 pack-years

1,327

20

4.00 (2.52-6.33)

279

4

4.05 (1.48-11.05)

434

7

4.15 (1.91-8.99)

614

9

4.44 (2.23-8.85)

<10

10,403

12

1.14 (0.64-2.03)

3,237

6

2.05 (0.89-4.70)

3,201

1

0.30 (0.04-2.14)

3,965

5

1.39 (0.56-3.43)

10-19

4,054

11

2.25 (1.23-4.12)

1,004

3

2.86 (0.90-9.05)

1,210

2

1.28 (0.31-5.20)

1,840

6

3.05 (1.33-7.00)

≥20

1,693

7

4.23 (1.99-8.98)

382

0

N/A

475

5

10.49 (4.25-25.9)

836

2

2.76 (0.68-11.23)

Pack-year

# of Cigarettes per day

a

Adjusted for age, educational level and body mass index
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Table 10. Lung cancer incidence and mortality rates and adjusted HR per tertile of serum total bilirubin level
among the male participants in the prospective cohort study by smoking status and smoking intensity

Characteristics

Men (N=202,902)
a

No. of lung cancer incidence

Adjusted HR (95% CI)

Incidence Rate Per 10 000 Person-Years (95% CI)

Total bilirubin level (mg/dL)

Total bilirubin level (mg/dL)

Total bilirubin level (mg/dL)

>1

0.75-1

<0.75

>1

0.75-1

<0.75

>1

0.75-1

<0.75

215

270

324

1 (Ref)

1.24 (1.03-1.51)

1.52 (1.26-1.82)

4.27 (3.71-4.90)

5.79 (5.12-6.54)

6.93 (6.20-7.75)

Non-smoker

64

50

42

1 (Ref)

0.86 (0.59-1.27)

0.84 (0.56-1.26)

2.56 (1.98-3.30)

2.46 (1.86-3.27)

2.35 (1.72-3.22)

Total smokers

139

202

262

1 (Ref)

1.29 (1.03-1.62)

1.55 (1.25-1.92)

6.05 (5.09-7.18)

8.37 (7.27-9.64)

9.75 (8.61-11.03)

<30 pack-years

27

47

49

1 (Ref)

1.71 (1.04-2.79)

1.77 (1.09-2.89)

1.57 (1.06-2.33)

2.74 (2.05-3.67)

2.61 (1.95-3.48)

≥30 pack-years

108

145

201

1 (Ref)

1.10 (0.85-1.43)

1.31 (1.03-1.67)

22.41 (18.46-27.21)

24.85 (21.05-29.35)

27.79 (24.11-32.02)

Total

a

No. of lung cancer mortality

Adjusted HR (95% CI)

Mortality Rate Per 10 000 Person-Years (95% CI)

Total bilirubin level (mg/dL)

Total bilirubin level (mg/dL)

Total bilirubin level (mg/dL)

>1

0.75-1

<0.75

>1

0.75-1

<0.75

>1

0.75-1

<0.75

147

214

253

1 (Ref)

1.39 (1.12-1.72)

1.71 (1.39-2.10)

2.70 (2.30-3.17)

4.11 (3.59-4.69)

4.88 (4.32-5.52)

Non-smoker

36

34

28

1 (Ref)

1.03 (0.65-1.65)

0.98 (0.59-1.61)

1.34 (0.96-1.85)

1.49 (1.06-2.09)

1.43 (0.99-2.07)

Total smokers

104

165

209

1 (Ref)

1.37 (1.07-1.76)

1.66 (1.31-2.10)

4.18 (3.45-5.07)

6.17 (5.30-7.19)

7.02 (6.13-8.04)

<30 pack-years

14

39

37

1 (Ref)

2.60 (1.41-4.80)

2.56 (1.38-4.74)

0.77 (0.45-1.30)

2.06 (1.51-2.82)

1.80 (1.31-2.49)

≥30 pack-years

89

119

162

1 (Ref)

1.09 (0.82-1.44)

1.32 (1.01-1.71)

16.54 (13.44-20.36)

18.02 (15.06-21.57)

20.13 (17.26-23.48)

Total

*Adjusted for age, educational level and body mass index
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Figure 5. Adjusted HRs of lung cancer incidence stratified by tertiles of
serum total bilirubin level and smoking pack-years (A) or cigarettes per day
(B) among male participants of the prospective cohort study.
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Figure 6. Adjusted HRs of lung cancer mortality stratified by tertiles of
serum total bilirubin level and smoking pack-years (A) or cigarettes per day
(B) among male participants of the prospective cohort study.
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Figure 7. Serum total bilirubin levels and lung cancer incidence rates (A)
and mortality rates (B) in overall males of the prospective cohort study.
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3.1.5. The ability of bilirubin in identifying smokers with higher risk of lung cancer
We then assessed the association between bilirubin levels and lung cancer
incidence or mortality rate stratified by smoking status. Among females, neither
non-smokers or smokers showed significant association, as only 17,123 (8.3%)
participants were smokers, and there were only 37 lung cancer cases among
them. Among males, the association was only present in smokers. Compared to
smokers with bilirubin levels in the highest tertile, smokers with bilirubin levels in
the middle and lowest tertiles had significantly increased lung cancer risk (HRs,
1.29 and 1.55) and mortality (HRs, 1.37 and 1.66) (Table 10). The risk appeared
to be stronger in light smokers: the HRs for the lowest tertile of bilirubin compared
to the highest tertile were 1.77 for incidence and 2.56 for mortality in smokers of
<30 pack years and 1.31 for incidence and 1.32 for mortality in smokers of ≥30
pack years, respectively (Table 10). We also plotted the lung cancer incidence
and mortality rates against subgroups of bilirubin levels in smokers and
introduced a best-fit model. Subjects with bilirubin levels <0.42 mg/dL showed
more than two folds increase in both lung cancer incidence rate (8.62 vs 3.76 per
100,000 person-years, Figure 7A) and mortality rate (6.27 vs 3.05 per 100,000
person-years, Figure 7B) compared to the subgroup with bilirubin levels >1.62
mg/dL. The associations between bilirubin level as a continuous variable and both
lung cancer incidence and lung cancer mortality were statistically significant in
males. The logistic regression model showed a 5% (95% CI, 3%-8%, P < 0.001)
increase in lung cancer incidence and 6% (95% CI, 3%-9%, P < 0.001) increase
in lung cancer mortality per 0.1 mg/dL decrease in bilirubin, after adjusting for age,
52

BMI and educational level. The interaction between bilirubin levels and smoking
status was not significant (log-likelihood test, P>0.05).
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Figure 8. Serum total bilirubin levels and lung cancer incidence rates (A)
and mortality rates (B) in male smokers of the prospective cohort study.
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3.2. Discussion
The purpose of this study is to identify biomarkers among serum
metabolites for lung cancer early diagnosis and to assist in identifying high-risk
individuals for lung cancer development. To our knowledge, this is the first study
that identified serum bilirubin as a lung cancer biomarker through unbiased global
metabolomic profiling. Furthermore, lower bilirubin was validated to confer an
increased risk for both lung cancer incidence and lung cancer specific mortality in
a large prospective cohort. When stratifying by smoking status, the association
was significant only in male ever-smokers. Through this multi-stage study, we
have identified and validated serum bilirubin as a risk predictor for lung cancer
incidence as well as mortality in male smokers. While smoking is a strong risk
factor for lung cancer and shows a dose-response relationship, the
smoking-related risk is particularly high among individuals with low levels of
serum bilirubin, a 55% increase among those with bilirubin <0.75 mg/dL. Smokers
with ≥30 pack years had a 4-fold increase in lung cancer risk, and within this
group, those with bilirubin of <0.75 mg/dL had a 31% higher risk compared to
those of >1 mg/dL. The potential of using serum bilirubin to identify smokers at
particularly high-risk for lung cancer over and above the risk associated with
heavy smoking is an important observation. The inverse relationship between
bilirubin levels and lung cancer can be translated into a 5% increase in lung
cancer risk and a 6% increase in lung cancer mortality for each 0.1 mg/dL
decrease in bilirubin levels. In most clinical settings, emphasis is placed on
elevated bilirubin for diagnosis of liver diseases; hence low values of bilirubin are
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generally ignored. Making use of low serum bilirubin values to counsel heavy
smokers who are at particularly high risk for lung cancer about smoking cessation
can be carried out easily in many clinic settings.
Our findings may also have implications for the LDCT screening for lung
cancer. It has been reported that LDCT screening prevented the most deaths from
lung cancer among participants with the highest risk for lung cancer deaths − 60%
of participants at the highest risk accounted for 88% of prevented lung-cancer
deaths (7). Based on our results, male smokers with bilirubin level <0.75 mg/dL
have a 66% increased risk for lung cancer mortality compared to those with
bilirubin level >1 mg/dL, and for heavy smokers of ≥30 pack-years, the hazard
ratio is smaller, but still significant (HR = 1.32, P < 0.001). Consideration of
bilirubin levels might improve identifying participants with the highest risk for lung
cancer mortality who would benefit the most from the screening, and help improve
the specificity of LDCT screening. Furthermore, bilirubin results could be used to
target and motivate both light and heavy smokers for smoking cessation. Indeed,
the ability of low bilirubin in predicting high risk of lung cancer was not limited to
smokers with ≥30 pack-years in our study. The relationship was seen for all
smokers, regardless of pack years of smoking.
Elevated levels of serum bilirubin have been associated with a lower risk of
respiratory diseases and lung cancer (23, 24). The mechanism of this association
was credited to the antioxidant and anti-inflammatory properties of bilirubin. One
study examined the association between serum bilirubin levels and all-cause,
cardiovascular, and cancer mortality in 10,000 Belgian individuals who had been
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followed up for 10 years (40). They found that higher bilirubin within the normal
range was associated with lower cancer mortality only in men. Another recent
large UK cohort study showed higher bilirubin levels within the normal-range were
associated with lower risks of respiratory diseases including chronic obstructive
pulmonary disease (COPD), lung cancer and all-cause mortality (41). While that
study examined risks of respiratory diseases and all-cause mortality, our study
focused on lung cancer incidence and lung cancer specific mortality. Interestingly,
the UK study found significant association between bilirubin and lung cancer
incidence in both men and women, while in our study only men exhibited
significant association. Similarly, the Belgian study also found significant inverse
association between bilirubin and cancer mortality only in men. It should be
pointed out that percentage (58%) of female ever-smokers in the UK study was
much higher than those of our study (8.3%) and the Belgian study (~25%). It is
possible that the associations found in both men and women in the UK study
reflect largely the associations between bilirubin levels and lung cancer incidence
in male and female smokers.
Neither the UK nor the Belgian study performed stratified analysis of
bilirubin and lung cancer risk by smoking status. Smoking significantly reduces
serum bilirubin level and simply adjusting for smoking status during the analyses
may not be sufficient to account for the effect of smoking on the association
between bilirubin and lung cancer incidence and mortality, as adjusting for
smoking in our study did not remove the association between bilirubin levels and
lung cancer incidence and mortality in men. Only by examining the association in
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smokers and non-smokers separately that we were able to detect the
bilirubin-lung cancer associations in the subgroup of male ever-smokers. Notably,
the association between bilirubin levels and lung cancer incidence and mortality
rate in male ever-smokers remained strong in a series of sensitivity analyses in
our study, including restricting bilirubin levels within the normal range, excluding
participants who had abnormal liver enzyme assays or blood counts, or adjusting
for more variables (drinking status, physical activity and systolic blood pressure)
(data not shown). As bilirubin is a commonly ordered laboratory test, uncovering
this potentially protective relationship is intriguing. This study, while in line with the
reported conclusion, is the first to study the role of bilirubin as a risk factor for lung
cancer mortality, to focus on the analysis in smokers in detail, and to quantify the
hazards of low bilirubin.
We conducted a series of sensitivity analyses to strengthen our conclusion.
We excluded participants with lung cancer diagnosed within 3 years of cohort
enrollment. We restricted bilirubin levels within normal range, excluding
participants with abnormal liver enzymes or blood counts. Additional variables
(drinking status, physical activity and systolic blood pressure) were adjusted in the
multivariable models. Results essentially remained unchanged after all of the
above sensitivity analyses were carried out.
Recently, several research groups had applied metabolomic profiling of
serum/plasma to unveil metabolic alterations associated with lung cancer. Hori
and colleagues performed metabolomic profiling of serum samples in a Japanese
case-control study using gas chromatography/mass spectrometry (GC/MS),
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which detected a total of only 58 metabolites in serum (45). Among these, the
levels of 23 metabolites were altered in lung cancer patients compared to healthy
controls (45). In another study conducted in Japan, Maeda et al. studied 21
plasma amino acids in NSCLC patients by liquid chromatography/mass
spectrometry (LC/MS) and showed that differences in the amino acid profiles
could be used for screening NSCLC (35). Jordan and colleagues used nuclear
magnetic resonance (NMR) to measure 21 metabolites and showed the potential
of serum metabolomics to differentiate between lung cancer subtypes and
between patients and controls (34). However, these studies were limited by the
small number of metabolites detected. Our global unbiased metabolomic profiling
approach identified 403 known metabolites from different stages of lung cancer,
yielding a comprehensive picture of the metabolic profile changes associated with
cancer progression. Validated with two additional study sets, bilirubin was found
and confirmed as the most significant biomarker for lung cancer, which was
further validated prospectively in a large cohort.
A few potential limitations should be considered in the interpretation of our
findings. First, while we observed significant inverse associations between serum
bilirubin levels and lung cancer in male smokers, the associations were not
statistically significant in female smokers, which was most likely due to the lack of
power resulting from a small number of female smokers (8.3% of total females)
and very few number of lung cancer cases (n=37) among them. Second, although
we observed an inverse relationship between bilirubin levels and lung cancer risk,
the causality of the association remains unclear. Low bilirubin level could be a
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consequence of cancer rather than a predisposing factor. It is noteworthy that the
significant risk remained after we excluded lung cancer occurring within three
years of the bilirubin tests. Third, only the bilirubin data at the time of enrollment
were analyzed. In a subset of subjects that had two bilirubin tests performed
longitudinally, we found highly correlative data, implying the stability of total
bilirubin results over time.
In summary, low levels of serum bilirubin are associated with higher risk for
lung cancer incidence and mortality in male smokers and can be used to identify
higher risk smokers for lung cancer development and mortality. Future
prospective studies that incorporate this variable into NLST selection criteria to
fully assess its potential use for LDCT screening are warranted.
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3.3. Clinical Laboratory Tests and Lung Cancer Clinical Outcome
3.3.1. Patient characteristics
This study included 2,675 NSCLC patients, among whom 623 (23.3%)
were early stage and 2,052 (77.6%) were advanced stage patients (Table 11).
Among early stage NSCLC patients, 313 (50.2%) were men and 310 (49.8%)
were women, with a mean age of 66.8 years. The median survival time (MST)
was 62.7 months, with a median follow-up time (MFT) of 36.8 months. Over 90%
of the patients had a history of smoking, with 316 (50.7%) being former smokers
and 246 (39.5%) being current smokers or having quit within one year prior to
diagnosis. Three Hundred and ninety-six (63.6%) of them had stage I NSCLC,
while the remaining 227 (36.4%) had stage II disease. Among them, over half
(51.8%) had adenocarcinoma and 33.4% had squamous cell carcinoma. Among
2,052 advanced stage patients, 1,125 (54.8%) were men and 927 (45.2%) were
women, with a mean age of 61.7 years. The MST and MFT were 13.8 and 13.0
months respectively. Eight hundred and nineteen (39.9%) of them were former
smokers and 880 (42.9%) were current smokers or had quit within one year prior
to diagnosis. There were 477 (23.2%) stage IIIA, 277 (13.5%) stage IIIB and
1,298 (63.3%) stage IV patients. Patients with adenocarcinoma or squamous
cancer carcinoma represented 55.8% (n=1,146) or 22.1% (n=454) of all advanced
stage patients, respectively. Among them, 1,192 (58.1%) received definitive
chemotherapy, 978 of which were platinum-based. There was no statistically
significant association between the routine pre-treatment laboratory tests
investigated and recurrence or survival of early stage NSCLC patients (data not
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shown), therefore, only results of advanced stage NSCLC patients are presented
in details.
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Table 11. Host characteristics of overall, early stage and late stage NSCLC
patients

All Stage

Variables

Early Stage

Late Stage

N (%)
Mean age, y (SD)

62.9 (11.0)

66.8 (10.0)

61.7 (11.0)

Male

1438 (53.8)

313 (50.2)

1125 (54.8)

Female

1237 (46.2)

310 (49.8)

927 (45.2)

2201 (82.3)

535 (85.9)

1666 (81.2)

Hispanic

107 (4.0)

19 (3.0)

88 (4.3)

Black

367 (13.7)

69 (11.1)

298 (14.5)

Never

413 (15.4)

61 ( 9.8)

352 (17.2)

Former

1135 (42.4)

316 (50.7)

819 (39.9)

Current

1126 (42.1)

246 (39.5)

880 (42.9)

Stage I

396 (14.8)

396 (63.6)

Stage II

227 (8.5)

227 (36.4)

Stage IIIA

477 (17.8)

477 (23.2)

Stage IIIB

277 (10.4)

277 (13.5)

Stage IV

1298 (48.5)

1298 (63.3)

Sex

Race
White

Smoking status

Clinical stage

Histology
Adenocarcinoma

1469 (54.9)

323 (51.8)

1146 (55.8)

Squamous

662 (24.7)

208 (33.4)

454 (22.1)

Others

544 (20.3)

92 (14.8)

452 (22.0)

0

539 (20.1)

153 (24.6)

386 (18.8)

1

1271 (47.5)

251 (40.3)

1020 (49.7)

2-4

421 (15.7)

63 (10.1)

358 (17.4)

Unknown

444 (16.6)

156 (25.0)

288 (14.0)

Well differentiated

130 (4.9)

64 (10.3)

66 (3.2)

Moderately differentiated

474 (17.7)

180 (28.9)

294 (14.3)

Poorly differentiated and undifferentiated

1128 (42.2)

258 (41.4)

870 (42.4)

Unknown

943 (35.3)

121 (19.4)

822 (40.1)

Performance Status (ECOG score)

Histology grade
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No. of metastasis
0

1537 (57.5)

622 (99.8)

915 (44.6)

1

742 (27.7)

1 ( 0.2)

741 (36.1)

2

262 ( 9.8)

0

262 (12.8)

≥3

134 ( 5.0)

0

134 ( 6.5)

No

2080 (77.8)

200 (32.1)

1880 (91.6)

Yes

595 (22.2)

423 (67.9)

172 (8.4)

No

1941 (72.6)

472 (75.8)

1469 (71.6)

Yes

734 (27.4)

151 (24.2)

583 (28.4)

No

1297 (48.5)

437 (70.1)

860 (41.9)

Yes

1378 (51.5)

186 (29.9)

1192 (58.1)

No

2174 (81.3)

577 (92.6)

1597 (77.8)

Yes

501 (18.7)

46 (7.4)

455 (22.2)

MST, mo

18.1

62.7

13.8

MFT, mo

16

36.8

13

Surgery

Radiation

Chemotherapy

Chemoradiation

Abbreviations: MST, median survival time; MFT, median follow-up time
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3.3.2. Association of pre-treatment laboratory test levels with survival of
advanced stage NSCLC patients
Among the seven routine clinical pre-treatment serum laboratory tests
analyzed, low albumin, high ALP and high LDH were found statistically
significantly associated with both 2-year and 5-year survival of advanced stage
NSCLC patients subsequently treated with platinum-based chemotherapy (Table
12), after adjusting for other factors, i.e. age, gender, ethnicity, smoking status,
clinical stage and treatment regimen. Lower than normal (<3.5 g/dL) serum
pre-treatment albumin levels were associated with 47% and 39% increase risk of
death at 2-year and 5-year survival of advanced stage NSCLC patients treated
with platinum-based chemotherapy. This corresponded to a MST of 11.6 months
among those with low serum albumin levels and a MST of 17.1 months among
those with normal serum albumin levels (log-rank test P < 0.01) (Figure 8A and
9A). Similarly, advanced stage NSCLC patients with elevated and higher than
normal serum ALP levels (>126 IU/L) or LDH levels (>618 IU/L) were at 31% or 60%
increased risk of death at two years than those with normal serum ALP or LDH
level, respectively. Similar increases were also found for 5-year survival among
those patients (Table 12). MST for patients with normal serum ALP levels was
17.4 months compared to 12.6 months for those with higher than normal ALP
levels (log-rank test P < 0.0001) (Figure 8B and 9B). Similarly, MST for patients
with normal serum LDH levels was 18.0 months compared to 12.3 months for
those with higher than normal LDH levels (log-rank test P < 0.0001) (Figure 8C
and 9C).
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Table 12. Laboratory test levels associated with 2-year and 5-year survival in advanced NSCLC patients treated
with platinum-based chemotherapy

2-year survival
Lab Test

Alive,

Dead,

5-year survival

Adjusted HRa

Log-rank
P

N (%)

N (%)

(95% CI)

≥3.5

328 (37.88)

538 (62.12)

1 (reference)

<3.5

19 (18.63)

83 (81.37)

1.47 (1.15-1.87)

38-126

302 (38.77)

477 (61.23)

1 (reference)

>126

47 (23.98)

149 (76.02)

1.31 (1.08-1.58)

≤618

299 (39.45)

459 (60.55)

1 (reference)

>618

47 (21.96)

167 (78.04)

1.60 (1.34-1.92)

Alive,

Dead,

Adjusted HRa

MST

Log-rank
P

P

N (%)

N (%)

(95% CI)

170 (19.63)

696 (80.37)

1 (reference)

9 (8.82)

93 (91.18)

1.39 (1.11-1.75)

154 (19.77)

625 (80.23)

1 (reference)

25 (12.76)

171 (87.24)

1.24 (1.04-1.48)

155 (20.45)

603 (79.55)

1 (reference)

24 (11.21)

190 (88.79)

1.56 (1.32-1.85)

MST
P

Albumin (g/dL)
17.1
0.002

11.6

5.75E-07

17.1
0.004

11.6

1.31E-06

ALP (IU/L)
17.4
0.006

12.6

1.16E-05

17.4
0.01

12.6

6.06E-05

LDH (IU/L)
18.0
3.51E-07

12.3

5.29E-09

Abbreviations: ALP, ; LDH,
a

Adjusted for age, gender, ethnicity, smoking status, clinical stage, performance status and treatment with radiation.
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18.0
1.74E-07

12.3

2.58E-08

Figure 9. Kaplan-Meier 2-year survival curves for patients with advanced
NSCLC treated with platinum-based chemotherapy grouped by individual
lab test level: (A) Albumin, (B) ALP, (C) LDH.
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Figure 10. Kaplan-Meier 5-year survival curves for patients with advanced
NSCLC treated with platinum-based chemotherapy grouped by individual
lab test level: (A) Albumin, (B) ALP, (C) LDH.
68

3.3.3. Cumulative effects of unfavorable laboratory test levels
We conducted joint analysis to investigate whether advanced stage
NSCLC patients with more unfavorable pre-treatment laboratory test levels were
more likely to suffer from death, and the results were statistically significant (Table
13). Compared to those with none of the three adverse laboratory test levels for
albumin, ALP and LDH, advanced stage NSCLC patients who had one adverse
laboratory test level had a 34% increase in risk of death at 2 years (HR = 1.34, 95%
CI: 1.12-1.60, P < 0.001). Those with more than one adverse laboratory test
levels were two folds more likely to die at 2 years (HR = 2.00, 95% CI: 1.57-2.56,
P < 0.0001). Similar results were also found for 5-year survival of these patients.
The corresponding MSTs were 19.6, 14.0 and 10.0 months for advanced stage
NSCLC patients with 0, 1 and ≥2 unfavorable pre-treatment laboratory test levels
(log-rank test P < 0.0001) (Figure 10A and 11A).
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Table 13. Cumulative effect of unfavorable laboratory test levels associated with 2-year and 5-year survival in
advanced NSCLC patients treated with platinum-based chemotherapy

5-year survival

2-year survival
No. of Adverse
Alive,

Dead,

Adjusted HRa

Lab Test

a

Log-rank
P

N (%)

N (%)

(95% CI)

0

247 (43.33)

323 (56.67)

1 (reference)

1

82 (28.28)

208 (71.72)

≥2

14 (13.73)

88 (86.27)

Alive,

Dead,

Adjusted HRa

MST

Log-rank
P

P

MST

N (%)

N (%)

(95% CI)

19.6

130 (22.81)

440 (77.19)

1 (reference)

1.34 (1.12-1.60)

1.29E-03 14.0

39 (13.45)

251 (86.55)

1.32 (1.12-1.55)

6.97E-04 14.0

2.00 (1.57-2.56)

2.68E-08 10.0

9 (8.82)

93 (91.18)

1.80 (1.43-2.27)

7.34E-07 10.0

1.90E-14

Adjusted for age, gender, ethnicity, smoking status, clinical stage, performance status and treatment with radiation.
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P
19.6

1.17E-12

Figure 11. Kaplan-Meier 2-year survival curves for patients with advanced
NSCLC treated with platinum-based chemotherapy grouped by cumulative
effect of adverse lab test (A) and lab-test based risk score (B).
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Figure 12. Kaplan-Meier 5-year survival curves for patients with advanced
NSCLC treated with platinum-based chemotherapy grouped by cumulative
effect of adverse lab test (A) and lab-test based risk score (B).
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3.3.4. Lab-test based risk score associated with survival of advanced NSCLC
patients
We generated a risk score based on the three pre-treatment serum
laboratory test levels associated with survival of advanced stage NSCLC patients
treated with platinum-based chemotherapy. Compared to those with a low-risk
score, patients with a high-risk score had 49% increased risk of death at two
years (HR = 1.49, 95% CI: 1.26-1.75, P < 0.0001). Similar results were found for
5-year survival of those patients (Table 14). Kaplan-Meier survival analysis
showed that the corresponding MST was 19.6 months for those with a low-risk
score and 12.8 months for those with a high-risk score (log-rank test P < 0.0001)
(Figure 10B and 11B).
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Table 14. Lab-test based risk score associated with 2-year and 5-year survival in advanced NSCLC patients treated
with platinum-based chemotherapy

2-year survival
Alive,

Dead,

Adjusted HRa

Risk Score

a

5-year survival
Log-rank
P

N (%)

N (%)

(95% CI)

Low

247 (43.33)

323 (56.67)

1 (reference)

High

96 (24.49)

296 (75.51)

1.49 (1.26-1.75)

Dead,

Adjusted HRa

MST

19.6
12.8

Log-rank
P

P

1.71E-06

Alive,

1.30E-11

N (%)

N (%)

(95% CI)

130 (22.81)

440 (77.19)

1 (reference)

48 (12.24)

344 (87.76)

1.42 (1.23-1.64)

Adjusted for age, gender, ethnicity, smoking status, clinical stage, performance status and treatment with radiation.
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MST
P
19.6

2.28E-06

12.8

7.92E-11

3.4. Discussion
In this study, we evaluated seven serum pre-treatment clinical laboratory
tests indicative of overall metabolic status and investigated their prognostic values
in 622 early stage and 2,053 advanced stage NSCLC patients. While we did not
observe any significant associations between any of these laboratory test levels
and recurrence or survival of early stage NSCLC patients, we identified and
confirmed three serum pre-treatment clinical laboratory test levels (lower than
normal levels of albumin, higher than normal levels of ALP and LDH) as
prognostic factors for advanced stage NSCLC patients treated with
platinum-based chemotherapy. Not only was each of the three clinical laboratory
tests significantly associated with overall survival among patients with advanced
stage NSCLC treated with platinum-based chemotherapy, there was also a
significant cumulative effect – those with two or more than two adverse laboratory
test levels were two-fold more likely to die at two years compared to those with
none of the adverse laboratory test levels, corresponding to a MST of 10.0
months and 19.6 months, respectively.
Serum albumin level has been used as a biomarker for long-term
nutritional status (46, 47). Serum albumin is produced in the liver and is the most
abundant protein in human plasma/serum. Its major functions include maintaining
the intravascular oncotic pressure of the blood compartment, transporting
molecules of low water solubility and serving as a free radical scavenger (48). In
adults, normal range of serum albumin is 3.5 to 5.0 g/dL. Low serum albumin level
(<3.5 g/dL in adults), also known as hypoalbuminemia, may be caused by liver
75

diseases, malabsorption, pregnancy, genetic variations, as well as cancers.
Albumin level is often used as an indicator for liver disease or acute infection (49,
50). It’s also closely correlated with malnutrition, which commonly occurs in
cancer patients resulting from the host response to the tumor as well as to
therapeutic treatments. Studies have investigated the association of malnutrition
with several clinical outcomes among cancer patients, including quality of life
(QOL), response to treatment as well as overall survival. Malnutrition has been
found to be associated with worse overall clinical outcomes, which includes worse
QOL and shorter overall survival among cancer patients. In addition,
hypoalbuminemia has also been shown to be associated with worse clinical
outcomes in cancer patients. Studies have shown that low serum albumin level is
a negative prognostic factor in several kinds of malignancies, including colorectal
cancer (51, 52), gastric cancer (53), pancreatic cancer and breast cancer (54).
Alkaline phosphatase (ALP) is a ubiquitous enzyme present in all human
body tissues, catalyzing hydrolysis of phosphate esters and removing phosphate
groups (also called “dephosphorylation”) from different types of molecules in an
alkaline environment (55). There are several different ALP isoenzymes,
depending on where it is produced in the body, e.g., hepatic ALP, placenta ALP or
bone ALP isoenzyme, etc. Among these, ALP levels are highest in liver and bone
tissues (56). Serum total ALP is often measured as part of routine liver panel tests
or when presented with symptoms of liver or bone disorders to screen for a variety
of liver or bone disorders, including extrahepatic bile obstruction, intrahepatic
cholestasis, hepatitis, and bone disorders, e.g. Paget's disease, etc (56). Serum
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total ALP levels have been shown to be elevated in several metastatic
malignancies (57, 58). Of note, bone-specific alkaline phosphatase (bALP), which
is produced by osteoblasts, is an indicator of osteoblastic activity and a marker of
bone formation. bALP levels have been shown to be significantly elevated in
patients with solid malignancies experiencing metastases to the bone (57-60).
Several studies have examined bALP as a potential marker to detect occult bone
metastases in patients with lung cancer (61-63). In NSCLC, patients with skeletal
metastases had significantly higher levels of bALP than those without skeletal
metastases (64). Moreover, Brown et. al showed that among 238 patients with
NSCLC or other solid tumors, high baseline serum bALP levels were significantly
associated with an increased risk of adverse outcomes, including skeletal-related
events (SREs), disease progression, and overall survival. Patients with high bALP
levels had a 1.5-fold increased risk of death (RR = 1.53, 95% CI: 1.15-2.03, P =
0.003) (57). In their study, serum bALP levels were assessed using a chemical
inhibition and differential inactivation assay (57, 65). While the results are
consistent with our finding and have a similar magnitude of relative risk, their
analysis was conducted on pooled NSCLC and other solid tumors together,
presumably because of the small sample size of NSCLC patients (N = 115). With
978 advanced stage NSCLC patients treated with platinum-based chemotherapy
in our study, our results may reflect a more accurate risk estimate and are more
statistically significant (HR = 1.38, P < 0.001). However, in our study, we didn’t
measure the levels of different ALP isoenzymes, and rather only assessed overall
serum ALP levels.
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Lactate dehydrogenase (LDH) is a glycolytic enzyme involved in the
conversion of pyruvate, which is the final product of the glycolysis pathway, and
lactate. LDH is ubiquitously expressed in human body cells and serves as a
general marker for tissue injuries since it is commonly released from the cells to
blood after tissue damage (36). Elevated serum LDH levels may be caused by
many pathologic conditions, including hemolytic anemia, myocardial infarction,
liver disease, pulmonary disease, kidney disease and many types of malignancies,
as cancer cells have a higher turnover rate (36). In addition, cancer cells have
been long known to reprogram their energy metabolism towards glycolysis even
under aerobic conditions, which was first observed and reported by Otto Warburg
in the 1930s (66, 67). Elevated serum LDH levels have been shown to be
associated with tumor mass, tumor aggressiveness and unfavorable prognosis in
several malignancies (68-70). Moreover, several studies have identified serum
LDH levels as a significant variable associated with survival in patients with
NSCLC as well (71, 72).
Our study adds significant value to the current literature body. First, this is
one of the largest studies investigating the prognostic values of pre-treatment
clinical laboratory test levels on NSCLC patients’ outcomes, thus statistically
powered to reveal significant associations. Moreover, of the three laboratory tests
identified (albumin, ALP and LDH), we found that not only did each of their
pre-treatment level affect survival of advanced stage NSCLC patients treated with
platinum-based chemotherapy, cumulatively patients with more adverse tests also
had worse overall survival. Furthermore, compared to other large studies
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investigating the roles of clinical laboratory test levels in NSCLC, our study has
the advantage that all patients were recruited from the same institution, thus
offering a more homogenous population in terms of quality of diagnosis, treatment,
laboratory test techniques and reference values used. These findings also have
practical importance in the clinical setting. Since these laboratory tests are
inexpensive, minimally invasive for the patients and routinely performed in the
clinical setting, their values can be easily assessed and evaluated. There are also
limitations with our study. Although all laboratory test levels were measured before
treatment, this study was designed retrospectively, therefore is susceptible to the
limitations of possible selection bias and reverse causation. Future prospective
studies investigating the prognostic values of clinical laboratory tests on NSCLC
outcomes are warranted.
In conclusion, in this study, we have utilized the large NSCLC patient
population at the University of Texas MD Anderson Cancer Center, and found
lower than normal albumin levels, higher than normal levels of ALP and LDH are
all significant adverse prognostic factors for advanced stage NSCLC patients
treated with platinum-based chemotherapy, both individually and cumulatively.
Our results suggested that pre-treatment clinical laboratory test levels could be
utilized to enhance predictions of survival among advanced stage NSCLC
patients treated with platinum-based chemotherapy.
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Chapter 4. Conclusions
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In conclusion, our studies have identified clinically relevant novel serum
biomarkers for lung cancer early diagnosis and clinical outcome. Through our
multi-phase study comprised of global metabolomic profiling and prospective
validation in a large cohort, we have identified and validated bilirubin as a risk
predictor for lung cancer incidence as well as mortality in smokers. Our results
suggested that low serum bilirubin levels can be used to identify higher risk
smokers for lung cancer. Addition of this variable into National Lung Screening
Trial (NLST) selection criteria for low-dose computed tomography (LDCT)
screening might help identify higher risk smokers who would benefit more from
LDCT screening and reduce false positives. We have also found that three
pre-treatment clinical laboratory test levels indicative of metabolic status were
both individually and jointly associated with overall survival among advanced
stage NSCLC patients treated with platinum-based chemotherapy. These tests
could further be utilized to enhance predictions of survival among advanced stage
NSCLC patients treated with platinum-based chemotherapy.
Taken together, our results suggested that metabolic alterations associated
with lung cancer could serve as novel serum biomarkers with clinical significance
for both lung cancer early detection and clinical outcome. With future prospective
validation studies, these biomarkers could be applied to the clinics to screen for
lung cancer at an early stage and to predict clinical outcome.
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Chapter 5. Future Directions

82

In the current studies, we investigated global metabolomic profiles of lung
cancer patients and matched controls and identified bilirubin as a biomarker for
lung cancer early diagnosis, which can be used to identify higher risk smokers for
lung cancer. For the future studies, our group is planning to determine the
sensitivity, specificity, positive predictive value and negative predictive value of
bilirubin as a lung cancer biomarker, and to incorporate bilirubin with other known
lung cancer risk factors into a risk prediction model for lung cancer risk prediction.
It would be also interesting to further conduct other “omic” profilings in these
samples, e.g. genomic, transcriptomic and proteomic profiling to identify
biomarkers at DNA, RNA and protein levels. Moreover, it would be of great
interest and value to correlate our metabolomics profiling data with these other
“omics” data to investigate the correlations among DNA, RNA, protein and
metabolite levels to identify and elucidate novel molecular pathways underlying
lung cancer development. In the future, we will also determine the metabolomic
profiles among lung cancer patients with different prognosis to identify novel
prognostic biomarkers for lung cancer clinical outcomes.
Our studies have also identified three clinical laboratory test levels as
biomarkers for advanced stage non-small cell lung cancer patients treated with
platinum-based chemotherapy. While this is one of the largest studies so far
investigating the association between clinical laboratory test levels and NSCLC
clinical outcomes, we will seek collaboration in other independent patient
populations with similarly detailed information on epidemiological and clinical
follow-up data as well as data on clinical laboratory test levels, to validate our
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findings. In addition, we will do the meta-analysis to further validate our results. In
the meanwhile, prospective studies, in which clinical laboratory test levels of
newly diagnosed NSCLC patients are recorded and the clinical outcomes of these
patients are followed up prospectively would significantly provide further support
to the research findings. Lastly, we will incorporate the clinical laboratory test
levels and other NSCLC prognostic factors to build a prediction model for NSCLC
patients’ survival prediction.
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Appendix B: Supplementary table
List of the 306 metabolites passing QC and their belonging pathways
Biochemical

Super-pathway

Sub-pathway

1,2-propanediol

Lipid

Ketone bodies

1,5-anhydroglucitol (1,5-AG)

Carbohydrate

1,6-anhydroglucose

Carbohydrate

1,7-dimethylurate

Xenobiotics

Xanthine metabolism

10-heptadecenoate (17:1n7)

Lipid

Long chain fatty acid

10-nonadecenoate (19:1n9)

Lipid

Long chain fatty acid

12-HETE

Lipid

Eicosanoid

13-HODE + 9-HODE

Lipid

Fatty acid, monohydroxy

13-methylmyristic acid

Lipid

Fatty acid, branched

17-methylstearate

Lipid

Fatty acid, branched

1-arachidonoyl-GPC* (20:4)*

Lipid

Lysolipid

1-arachidonoyl-GPE* (20:4)*

Lipid

Lysolipid
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Glycolysis, gluconeogenesis, pyruvate
metabolism
Glycolysis, gluconeogenesis, pyruvate
metabolism

1-arachidonoyl-GPI* (20:4)*

Lipid

Lysolipid

1-docosahexaenoyl-GPC* (22:6)*

Lipid

Lysolipid

1-docosapentaenoyl-GPC* (22:5)*

Lipid

Lysolipid

1-eicosatrienoyl-GPC* (20:3)*

Lipid

Lysolipid

1-heptadecanoyl-GPC (17:0)

Lipid

Lysolipid

1-linoleoylglycerol (18:2)

Lipid

Monoacylglycerol

1-linoleoyl-GPC (18:2)

Lipid

Lysolipid

1-linoleoyl-GPE (18:2)*

Lipid

Lysolipid

1-methyladenosine

Nucleotide

Purine metabolism, adenine containing

1-myristoyl-GPC (14:0)

Lipid

Lysolipid

1-oleoylglycerol (18:1)

Lipid

Monoacylglycerol

1-oleoyl-GPC (18:1)

Lipid

Lysolipid

1-oleoyl-GPE (18:1)

Lipid

Lysolipid

1-palmitoleoyl-GPC* (16:1)*

Lipid

Lysolipid

1-palmitoylglycerol (16:0)

Lipid

Monoacylglycerol

1-palmitoyl-GPC (16:0)

Lipid

Lysolipid

1-palmitoyl-GPE (16:0)

Lipid

Lysolipid

1-palmitoyl-GPI* (16:0)*

Lipid

Lysolipid

1-palmitoylplasmenylethanolamine*

Lipid

Lysolipid
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1-pentadecanoylglycerophosphocholine*

Lipid

Lysolipid

1-stearoylglycerol (18:0)

Lipid

Monoacylglycerol

1-stearoyl-GPC (18:0)

Lipid

Lysolipid

1-stearoyl-GPE (18:0)

Lipid

Lysolipid

1-stearoyl-GPI (18:0)

Lipid

Lysolipid

2-aminobutyrate

Amino acid

Butanoate metabolism

2-arachidonoyl-GPC* (20:4)*

Lipid

Lysolipid

2-arachidonoyl-GPE* (20:4)*

Lipid

Lysolipid

2-ethylhexanoic acid

Xenobiotics

Chemical

2-hydroxybutyrate (AHB)

Amino acid

Cysteine, methionine, SAM, taurine metabolism

2-hydroxyglutarate

Lipid

Fatty acid, dicarboxylate

2-hydroxyisobutyrate

Amino acid

Valine, leucine and isoleucine metabolism

2-hydroxypalmitate

Lipid

Fatty acid, monohydroxy

2-hydroxystearate

Lipid

Fatty acid, monohydroxy

2-linoleoyl-GPC* (18:2)*

Lipid

Lysolipid

2-linoleoyl-GPE* (18:2)*

Lipid

Lysolipid

2-methylbutyroylcarnitine (C5)

Amino acid

Valine, leucine and isoleucine metabolism

2-oleoyl-GPC* (18:1)*

Lipid

Lysolipid

2-oleoyl-GPE* (18:1)*

Lipid

Lysolipid
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2-palmitoyl-GPC* (16:0)*

Lipid

Lysolipid

2-palmitoyl-GPE* (16:0)*

Lipid

Lysolipid

2-pyrrolidinone

Xenobiotics

Chemical

2-stearoyl-GPC* (18:0)*

Lipid

Lysolipid

3-(4-hydroxyphenyl)lactate (HPLA)

Amino acid

Phenylalanine & tyrosine metabolism

Lipid

Fatty acid, dicarboxylate

3-dehydrocarnitine*

Lipid

Carnitine metabolism

3-hydroxy-2-ethylpropionate

Amino acid

Valine, leucine and isoleucine metabolism

3-hydroxybutyrate (BHBA)

Lipid

Ketone bodies

3-hydroxyisobutyrate

Amino acid

Valine, leucine and isoleucine metabolism

3-hydroxylaurate

Lipid

Fatty acid, monohydroxy

3-indoxyl sulfate

Amino acid

Tryptophan metabolism

3-methoxytyrosine

Amino acid

Phenylalanine & tyrosine metabolism

3-methyl-2-oxobutyrate

Amino acid

Valine, leucine and isoleucine metabolism

3-methyl-2-oxovalerate

Amino acid

Valine, leucine and isoleucine metabolism

3-methylhistidine

Amino acid

Histidine metabolism

4-acetamidobutanoate

Amino acid

Guanidino and acetamido metabolism

4-androsten-3beta,17beta-diol disulfate 1*

Lipid

Sterol/Steroid

3-carboxy-4-methyl-5-propyl-2-furanpropanoate
(CMPF)
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4-androsten-3beta,17beta-diol disulfate 2*

Lipid

Sterol/Steroid

4-hydroxyphenylacetate

Amino acid

Phenylalanine & tyrosine metabolism

4-methyl-2-oxopentanoate

Amino acid

Valine, leucine and isoleucine metabolism

5-dodecenoate (12:1n7)

Lipid

Medium chain fatty acid

5-oxoproline

Amino acid

Glutathione metabolism

7-HOCA

Lipid

Sterol/Steroid

acetylcarnitine (C2)

Lipid

Carnitine metabolism

acetylphosphate

Energy

Oxidative phosphorylation

adrenate (22:4n6)

Lipid

Long chain fatty acid

ADSGEGDFXAEGGGVR*

Peptide

Fibrinogen cleavage peptide

alanine

Amino acid

Alanine and aspartate metabolism

allantoin

Nucleotide

Purine metabolism, urate metabolism

alpha-hydroxyisovalerate

Amino acid

Valine, leucine and isoleucine metabolism

alpha-ketoglutarate

Energy

Krebs cycle

alpha-tocopherol

Cofactors and vitamins

Tocopherol metabolism

andro steroid monosulfate 2*

Lipid

Sterol/Steroid

androsterone sulfate

Lipid

Sterol/Steroid

arabinose

Carbohydrate

Nucleotide sugars, pentose metabolism

arabitol

Carbohydrate

Nucleotide sugars, pentose metabolism
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arachidonate (20:4n6)

Lipid

Long chain fatty acid

arginine

Amino acid

Urea cycle; arginine-, proline-, metabolism

ascorbate (Vitamin C)

Cofactors and vitamins

Ascorbate and aldarate metabolism

asparagine

Amino acid

Alanine and aspartate metabolism

aspartate

Amino acid

Alanine and aspartate metabolism

aspartylphenylalanine

Peptide

Dipeptide

azelate (nonanedioate; C9)

Lipid

Fatty acid, dicarboxylate

benzoate

Xenobiotics

Benzoate metabolism

beta-alanine

Amino acid

Alanine and aspartate metabolism

beta-hydroxyisovalerate

Amino acid

Valine, leucine and isoleucine metabolism

betaine

Amino acid

Glycine, serine and threonine metabolism

bilirubin

Cofactors and vitamins

Hemoglobin and porphyrin metabolism

bilirubin (E,E)*

Cofactors and vitamins

Hemoglobin and porphyrin metabolism

bradykinin, des-arg(9)

Peptide

Polypeptide

butyrylcarnitine (C4)

Lipid

Fatty acid metabolism (also BCAA metabolism)

caffeine

Xenobiotics

Xanthine metabolism

campesterol

Lipid

Sterol/Steroid

caprate (10:0)

Lipid

Medium chain fatty acid

caproate (6:0)

Lipid

Medium chain fatty acid
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caprylate (8:0)

Lipid

Medium chain fatty acid

carnitine

Lipid

Carnitine metabolism

catechol sulfate

Xenobiotics

Benzoate metabolism

C-glycosyltryptophan*

Amino acid

Tryptophan metabolism

cholesterol

Lipid

Sterol/Steroid

choline

Lipid

Glycerolipid metabolism

cis-4-decenoyl carnitine

Lipid

Carnitine metabolism

cis-aconitate

Energy

Krebs cycle

citrate

Energy

Krebs cycle

citrulline

Amino acid

Urea cycle; arginine-, proline-, metabolism

cortisol

Lipid

Sterol/Steroid

cortisone

Lipid

Sterol/Steroid

creatine

Amino acid

Creatine metabolism

creatinine

Amino acid

Creatine metabolism

cyclo(phe-phe)

Peptide

Dipeptide

cysteine

Amino acid

Cysteine, methionine, SAM, taurine metabolism

cystine

Amino acid

Cysteine, methionine, SAM, taurine metabolism

decanoylcarnitine (C10)

Lipid

Carnitine metabolism

dehydroisoandrosterone sulfate (DHEA-S)

Lipid

Sterol/Steroid
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deoxycarnitine

Lipid

Carnitine metabolism

deoxycholate

Lipid

Bile acid metabolism

dihomolinoleate (20:2n6)

Lipid

Long chain fatty acid

dihomolinolenate (20:3n3 or 3n6)

Lipid

Essential fatty acid

dimethylarginine (ADMA + SDMA)

Amino acid

Urea cycle; arginine-, proline-, metabolism

dimethylglycine

Amino acid

Glycine, serine and threonine metabolism

docosadienoate (22:2n6)

Lipid

Long chain fatty acid

docosahexaenoate (DHA; 22:6n3)

Lipid

Essential fatty acid

docosapentaenoate (DPA; 22:5n3)

Lipid

Essential fatty acid

docosapentaenoate (n6 DPA; 22:5n6)

Lipid

Essential fatty acid

dodecanedioate (C12)

Lipid

Fatty acid, dicarboxylate

DSGEGDFXAEGGGVR*

Peptide

Fibrinogen cleavage peptide

eicosapentaenoate (EPA; 20:5n3)

Lipid

Essential fatty acid

eicosenoate (20:1n9 or 1n11)

Lipid

Long chain fatty acid

epiandrosterone sulfate

Lipid

Sterol/Steroid

erythritol

Xenobiotics

Sugar, sugar substitute, starch

erythronate*

Carbohydrate

Aminosugars metabolism

ethanolamine

Lipid

Glycerolipid metabolism

fructose

Carbohydrate

Fructose, mannose, galactose, starch, and
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sucrose metabolism
fucose

Carbohydrate

Aminosugars metabolism

fumarate

Energy

Krebs cycle

gamma-CEHC

Cofactors and vitamins

Tocopherol metabolism

gamma-glutamylalanine

Peptide

gamma-glutamyl

gamma-glutamylglutamine

Peptide

gamma-glutamyl

gamma-glutamylleucine

Peptide

gamma-glutamyl

gamma-glutamylmethionine

Peptide

gamma-glutamyl

gamma-glutamylphenylalanine

Peptide

gamma-glutamyl

gamma-glutamylthreonine*

Peptide

gamma-glutamyl

gamma-glutamyltyrosine

Peptide

gamma-glutamyl

gamma-glutamylvaline

Peptide

gamma-glutamyl

gamma-tocopherol

Cofactors and vitamins

Tocopherol metabolism

gluconate

Carbohydrate

Nucleotide sugars, pentose metabolism

glucose

Carbohydrate

glucuronate

Carbohydrate

glutamate

Amino acid
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Glycolysis, gluconeogenesis, pyruvate
metabolism
Glycolysis, gluconeogenesis, pyruvate
metabolism
Glutamate metabolism

glutamine

Amino acid

Glutamate metabolism

glutaroylcarnitine (C5)

Amino acid

Lysine metabolism

glycerate

Carbohydrate

glycerol

Lipid

Glycerolipid metabolism

glycerol 2-phosphate

Xenobiotics

Chemical

glycerol 3-phosphate (G3P)

Lipid

Glycerolipid metabolism

glycerophosphorylcholine (GPC)

Lipid

Glycerolipid metabolism

glycine

Amino acid

Glycine, serine and threonine metabolism

glycochenodeoxycholate

Lipid

Bile acid metabolism

glycocholate

Lipid

Bile acid metabolism

glycocholenate sulfate*

Lipid

Bile acid metabolism

glycodeoxycholate

Lipid

Bile acid metabolism

glycolate (hydroxyacetate)

Xenobiotics

Chemical

glycolithocholate sulfate*

Lipid

Bile acid metabolism

glycoursodeoxycholate

Lipid

Bile acid metabolism

glycylphenylalanine

Peptide

Dipeptide

glycylvaline

Peptide

Dipeptide

heme*

Cofactors and vitamins

Hemoglobin and porphyrin
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Glycolysis, gluconeogenesis, pyruvate
metabolism

heptanoate (7:0)

Lipid

Medium chain fatty acid

hexadecanedioate (C16)

Lipid

Fatty acid, dicarboxylate

hexanoylcarnitine (C6)

Lipid

Carnitine metabolism

hippurate

Xenobiotics

Benzoate metabolism

histidine

Amino acid

Histidine metabolism

homostachydrine*

Xenobiotics

Food component/Plant

HWESASXX*

Peptide

Polypeptide

hydroxyproline

Amino acid

Urea cycle; arginine-, proline-, metabolism

hypoxanthine

Nucleotide

indoleacetate

Amino acid

Tryptophan metabolism

indolelactate

Amino acid

Tryptophan metabolism

indolepropionate

Amino acid

Tryptophan metabolism

inosine

Nucleotide

inositol 1-phosphate (I1P)

Lipid

Inositol metabolism

isobutyrylcarnitine (C4)

Amino acid

Valine, leucine and isoleucine metabolism

isoleucine

Amino acid

Valine, leucine and isoleucine metabolism

isovalerylcarnitine (C5)

Amino acid

Valine, leucine and isoleucine metabolism

Purine metabolism, (hypo)xanthine/inosine
containing

Purine metabolism, (hypo)xanthine/inosine
containing

108

kynurenine

Amino acid

lactate

Carbohydrate

lathosterol

Lipid

Sterol/Steroid

laurate (12:0)

Lipid

Medium chain fatty acid

leucine

Amino acid

Valine, leucine and isoleucine metabolism

leucylleucine

Peptide

Dipeptide

levulinate (4-oxovalerate)

Amino acid

Valine, leucine and isoleucine metabolism

linoleate (18:2n6)

Lipid

Essential fatty acid

linolenate (18:3n3 or 3n6)

Lipid

Essential fatty acid

lysine

Amino acid

Lysine metabolism

malate

Energy

Krebs cycle

mannitol

Carbohydrate

mannose

Carbohydrate

margarate (17:0)

Lipid

Long chain fatty acid

methionine

Amino acid

Cysteine, methionine, SAM, taurine metabolism

methyl palmitate (15 or 2)

Lipid

Fatty acid, branched
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Tryptophan metabolism
Glycolysis, gluconeogenesis, pyruvate
metabolism

Fructose, mannose, galactose, starch, and
sucrose metabolism
Fructose, mannose, galactose, starch, and
sucrose metabolism

methyl palmitate (16:0)

Lipid

Fatty acid, methyl ester

methylphosphate

Nucleotide

Purine and pyrimidine metabolism

myo-inositol

Lipid

Inositol metabolism

myristate (14:0)

Lipid

Long chain fatty acid

myristoleate (14:1n5)

Lipid

Long chain fatty acid

N6-acetyllysine

Amino acid

Lysine metabolism

N-acetylalanine

Amino acid

Alanine and aspartate metabolism

N-acetyl-beta-alanine

Amino acid

Alanine and aspartate metabolism

N-acetylglycine

Amino acid

Glycine, serine and threonine metabolism

N-acetylmethionine

Amino acid

Cysteine, methionine, SAM, taurine metabolism

N-acetylneuraminate

Carbohydrate

Aminosugars metabolism

N-acetylornithine

Amino acid

Urea cycle; arginine-, proline-, metabolism

N-acetylserine

Amino acid

Glycine, serine and threonine metabolism

N-acetylthreonine

Amino acid

Glycine, serine and threonine metabolism

N-formylmethionine

Amino acid

Cysteine, methionine, SAM, taurine metabolism

nicotinamide

Cofactors and vitamins

Nicotinate and nicotinamide metabolism

nonadecanoate (19:0)

Lipid

Long chain fatty acid

octadecanedioate (C18)

Lipid

Fatty acid, dicarboxylate

octanoylcarnitine (C8)

Lipid

Carnitine metabolism
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oleate (18:1n9)

Lipid

Long chain fatty acid

oleoylcarnitine (C18)

Lipid

Carnitine metabolism

ornithine

Amino acid

Urea cycle; arginine-, proline-, metabolism

oxalate (ethanedioate)

Carbohydrate

Glyoxylate and dicarboxylate metabolism

palmitate (16:0)

Lipid

Long chain fatty acid

palmitoleate (16:1n7)

Lipid

Long chain fatty acid

palmitoyl sphingomyelin

Lipid

Sphingolipid

palmitoylcarnitine (C16)

Lipid

Carnitine metabolism

pantothenate (Vitamin B5)

Cofactors and vitamins

Pantothenate and CoA metabolism

paraxanthine

Xenobiotics

Xanthine metabolism

p-cresol sulfate

Amino acid

Phenylalanine & tyrosine metabolism

pelargonate (9:0)

Lipid

Medium chain fatty acid

pentadecanoate (15:0)

Lipid

Long chain fatty acid

phenol sulfate

Amino acid

Phenylalanine & tyrosine metabolism

phenylacetylglutamine

Amino acid

Phenylalanine & tyrosine metabolism

phenylalanine

Amino acid

Phenylalanine & tyrosine metabolism

phenylalanylleucine*

Peptide

Dipeptide

phenylalanylphenylalanine

Peptide

Dipeptide

phenyllactate (PLA)

Amino acid

Phenylalanine & tyrosine metabolism
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phosphate

Energy

Oxidative phosphorylation

pipecolate

Amino acid

Lysine metabolism

piperine

Xenobiotics

Food component/Plant

pregn steroid monosulfate*

Lipid

Sterol/Steroid

pregnen-diol disulfate*

Lipid

Sterol/Steroid

pregnenolone sulfate

Lipid

Sterol/Steroid

proline

Amino acid

Urea cycle; arginine-, proline-, metabolism

prolylhydroxyproline

Peptide

Dipeptide

propionylcarnitine (C3)

Lipid

Fatty acid metabolism (also BCAA metabolism)

pseudouridine

Nucleotide

Pyrimidine metabolism, uracil containing

pyridoxate

Cofactors and vitamins

Vitamin B6 metabolism

pyroglutamine*

Amino acid

Glutamate metabolism

pyroglutamylglycine

Peptide

Dipeptide

pyrophosphate (PPi)

Energy

Oxidative phosphorylation

pyruvate

Carbohydrate

quinate

Xenobiotics

Food component/Plant

ribitol

Carbohydrate

Nucleotide sugars, pentose metabolism

ribose

Carbohydrate

Nucleotide sugars, pentose metabolism
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Glycolysis, gluconeogenesis, pyruvate
metabolism

scyllo-inositol

Lipid

Inositol metabolism

sebacate (decanedioate)

Lipid

Fatty acid, dicarboxylate

serine

Amino acid

Glycine, serine and threonine metabolism

serotonin (5HT)

Amino acid

Tryptophan metabolism

S-methylcysteine

Amino acid

Cysteine, methionine, SAM, taurine metabolism

sphingomyelin

Lipid

Sphingolipid

stachydrine

Xenobiotics

Food component/Plant

stearamide

Lipid

Fatty acid, amide

stearate (18:0)

Lipid

Long chain fatty acid

stearidonate (18:4n3)

Lipid

Long chain fatty acid

stearoylcarnitine (C18)

Lipid

Carnitine metabolism

suberate (octanedioate)

Lipid

Fatty acid, dicarboxylate

succinate

Energy

Krebs cycle

succinylcarnitine (C4)

Energy

Krebs cycle

sucrose

Carbohydrate

taurochenodeoxycholate

Lipid

Bile acid metabolism

taurocholenate sulfate*

Lipid

Bile acid metabolism

taurodeoxycholate

Lipid

Bile acid metabolism
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Fructose, mannose, galactose, starch, and
sucrose metabolism

taurolithocholate 3-sulfate

Lipid

Bile acid metabolism

theobromine

Xenobiotics

Xanthine metabolism

theophylline

Xenobiotics

Xanthine metabolism

threitol

Carbohydrate

Nucleotide sugars, pentose metabolism

threonate

Cofactors and vitamins

Ascorbate and aldarate metabolism

threonine

Amino acid

Glycine, serine and threonine metabolism

triethyleneglycol

Xenobiotics

Chemical

trizma acetate

Xenobiotics

Chemical

tryptophan

Amino acid

Tryptophan metabolism

tryptophan betaine

Amino acid

Tryptophan metabolism

tyrosine

Amino acid

Phenylalanine & tyrosine metabolism

undecanedioate

Lipid

Fatty acid, dicarboxylate

undecanoate (11:0)

Lipid

Medium chain fatty acid

urate

Nucleotide

Purine metabolism, urate metabolism

urea

Amino acid

Urea cycle; arginine-, proline-, metabolism

uridine

Nucleotide

Pyrimidine metabolism, uracil containing

vaccenate (18:1n7)

Lipid

Long chain fatty acid

valine

Amino acid

Valine, leucine and isoleucine metabolism

xanthine

Nucleotide

Purine metabolism, (hypo)xanthine/inosine
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containing
xylonate

Carbohydrate

Nucleotide sugars, pentose metabolism

xylose

Carbohydrate

Nucleotide sugars, pentose metabolism
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